 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   1 of 90 
CLINICAL TRIAL PROTOCOL  
A Multicenter, Randomized, Double -Blind, Placebo -
Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in 
Subjects with Non- Alcoholic Steatohepatitis (NASH)  
Cirrhosis and Severe Portal Hypertension  
Protocol Number:  IDN-6556- 14 
EudraCT Number:  2015- 004473- 32 
Developmental Phase:  2 
Amendment 8 (Version 9.0)  14 March 2018  
Amendment 7 (Version 8.0)  22 January 2018  
Amendment 6 (Version 7.0)  18 October 2017  
Amendment 5 (Version 6.0)  13 July 2017  
Amendment 4 (Version 5 .0) 26 May 2017  
Amendment 3 (Version 4.0)  10 April 2017  
Amendment 2 (Version 3.0)  07 March 2017  
Amendment 1 (Version 2.0)  15 June 2016  
Original Protocol  (Version 1.0)  29 March 2016  
Draft Protocol  02 February 2016  
Sponsor:  Conatus Pharmaceuticals Inc.  
16745 W. Bernardo Drive, Suite 200  
San Diego, CA 92127  
USA 
 
THIS PROTOCOL IS THE PROPERTY OF CONATUS PHARMACEUTICALS AND IS A CONFIDENTIAL COMMUNICATION. 
ACCEPTANCE IMPLIES AN AGREEMENT NOT  TO DISCLOSE INFORMATION CONTAINED HEREIN THAT IS NOT 
OTHERWISE PUBLICLY AVAILABLE, EXCEPT FOR USE BY AN INSTITUTIONAL REVIEW BOARD (IRB) OR ETHICS 
COMMITTEE (EC) FOR THE PURPOSE OF OBTAINING APPROVAL TO CONDUCT THE STUDY. THE IRB/IEC IS REQUESTED AND EXPECTED TO MAINTAIN CONFIDENTIALITY. THIS DOCUMENT MAY NOT BE USED OR PUBLISHED 
IN WHOLE OR IN PART WITHOUT THE WRITTEN CONSENT OF CONATUS PHARMACEUTICALS.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   2 of 90 
KEY PERSONNEL  
Sponsor  
Conatus Pharmaceuticals  Inc. 
16745 W. Bernardo Drive, Suite 200  
San Diego, CA 92127  
USA 
 
Sponsor Contact  
Jean L. Chan, MD  
VP, Clinical Development  
Office:  +1-858 376 2632  
Mobile:  +1-617 407 5689  
jchan@conatuspharma.com  
 
Pharmacovigilance, 24 H our Emergency Reporting  
SynteractHCR Safety  
Safety Fax:  +1-760-268-6500  
safetyfax@synteract hcr.com  OR 
if not 
available  Mason Yamashita, MD  
VP, Pharmacovigilance 
Office:  +1-858 376 2617  
Mobile:  +1-619 306 2125  
myamashita@conatuspharma.com  
 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   3 of 90 
TABLE OF CONTENTS  
1 STUDY SYNOPSIS  ............................................................................................................... 7 
2 LIST OF ABBREVIATION S .................................................................................................  14 
3 ETHICS  ............................................................................................................................... 17 
4 INTRODUCTION  ................................................................................................................. 18 
4.1 Background  ............................................................................................................. 18 
4.2 Study Rationale ....................................................................................................... 20 
5 STUDY OBJECTIVES ......................................................................................................... 26 
6 STUDY DESIGN  ................................................................................................................. 27 
7 STUDY POPULA TION  ........................................................................................................ 30 
7.1 Inclusion Criteria  ...................................................................................................... 30 
7.2 Exclusion Criteria  ..................................................................................................... 31 
7.3 Subject Identification  ................................................................................................ 32 
7.4 Randomization Procedure ....................................................................................... 32 
7.5 Blinding/Unblinding Procedures  ............................................................................... 33 
8 STUDY ASSESSMENTS AN D CONDUCT  ......................................................................... 34 
8.1 Safety Assessments  ................................................................................................ 34 
8.1.1  Adverse Events  .................................................................................................. 34 
8.1.2  Medical History and Physical Examinations  ....................................................... 34 
8.1.3  Vital Sign Measurements  ................................................................................... 34 
8.1.4  12-Lead Electrocardiogram (ECG)  ..................................................................... 34 
8.1.5  Monitoring for Potential Gallbladder Adverse Effects  ......................................... 35 
8.1.6  Monitoring for Evidence of Potential Drug- Induced Li ver Injury (DILI)  ................ 35 
8.1.7  Management of Subjects Who Progress to Child- Pugh C  .................................. 39 
8.1.8  Screening and Follow -up Questionnaires for Alcohol Abuse .............................. 39 
8.1.9  Screening Esophagogastroduodenoscopy (EGD)  .............................................. 40 
8.2 Efficacy Assessments  .............................................................................................. 40 
8.2.1  Hepatic Venous Pressure Gradient (HVPG)  ....................................................... 40 
8.2.2  Model for End Stage Liver Disease [1] Score  ..................................................... 41 
8.2.3  Child -Pugh Score and Classification  .................................................................. 42 
8.2.4  Quality of Life Assessments  ............................................................................... 43 
8.2.5  Clinical Outcome Events  .................................................................................... 44 
8.2.6  Liver Metabolic Function by Methacetin Breath Test  ..........................................  45 
8.2.7  Liver Stiffness by Transient Elastography (using FibroScan®) ............................ 45 
8.3 Laboratory Tests  ...................................................................................................... 46 
8.3.1  Biomarker Assessments  .................................................................................... 48 
8.3.2  Population Pharmacokinetic (PK) Assessment  .................................................. 48 
8.3.3  OATP Transporter Genotyping ........................................................................... 48 
8.3.4  Blood Volume .................................................................................................... 48 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   4 of 90 
8.4 Specific Study Visit Information  ................................................................................ 50 
8.4.1  Screening Phase (Week - 6 to Day 0)  .................................................................  50 
8.4.2  Double- Blind Phase (Day 1)  ............................................................................... 50 
8.4.3  Double- Blind Phase (Week 4)  ............................................................................ 51 
8.4.4  Initial 24 -Week Double- Blind Phase (Week 8, Week 12, Week  16, Week 20)  .... 51 
8.4.5  Initial 24 -Week Double- Blind Phase (Week 24)  .................................................. 51 
8.4.6  Continued 24- Week Double -Blind Phase (Week  32 and Week  40) .................... 52 
8.4.7  Continued 24- Week Double -Blind Phase (Week 48)  .......................................... 52 
8.4.8  Follow -Up Phase (2 weeks after Week 24 or Week 48)  ..................................... 53 
8.5 Prior and Concomitant Medications  ......................................................................... 53 
8.6 Other Precautions and Restrictions during the Study  ............................................... 53 
8.7 Subject and Study Termination ................................................................................ 54 
8.7.1  Reasons and Procedures for Early Termination  ................................................. 54 
8.7.2  Withdrawal from Study Drug Treatment but Not from Study Participation  .......... 54 
8.7.3  Termination of the Study  .................................................................................... 55 
9 INVESTIGATIONAL MEDI CINAL PRODUCT  ...................................................................... 56 
9.1 Emricasan and Placebo Supplies  ............................................................................ 56 
9.2 Investigational Medicinal Product Packaging and Labeling  ...................................... 56 
9.3 Investigational Medicinal Product Dispensing and Accountability  ............................. 56 
9.4 Investigational Medicinal Product Administration ..................................................... 56 
10 WARNINGS AND PRECAUT IONS  ..................................................................................... 57 
10.1  Teratogenicity and Fertility  ....................................................................................... 57 
10.2  Contraception for Female Subjects of Reproductive Potential  .................................  57 
10.3  Contraception for Male Subjects with Female Partners of Reproductive Potential  ... 59 
10.4  Use of Estrogens in Subjects with Decompensated Cirrhosis  .................................. 59 
11 DOCUM ENTATION OF DATA  ............................................................................................  60 
11.1  Source Documentation ............................................................................................  60 
11.2  Data Entry in Database  ............................................................................................  60 
11.3  Query Checks  .......................................................................................................... 60 
11.4  Coding of Adverse Events, Drugs, and Diseases  ..................................................... 60 
11.5  Study Language and Translations  ........................................................................... 60 
12 STATISTICAL METHODS  ................................................................................................... 61 
12.1  Introduction  .............................................................................................................. 61 
12.2  Parameters of Interest  ............................................................................................. 61 
12.2.1  Safety Variables  .................................................................................................  61 
12.2.2  Efficacy Variables  .............................................................................................. 61 
12.3  Analysis Populations  ................................................................................................ 62 
12.4  Sample Size  ............................................................................................................ 62 
12.5  Statistical Analyses  .................................................................................................. 62 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   5 of 90 
12.5.1  General  .............................................................................................................. 62 
12.5.2  Safety Analysis  .................................................................................................. 63 
12.5.3  Efficacy Analysis  ................................................................................................ 63 
12.5.4  Timing of Analyses  ............................................................................................. 64 
12.6  Handling of Missing Data  ......................................................................................... 64 
12.7  Data Monitoring Committee (DMC)  .......................................................................... 65 
13 SAFETY MONITORING AN D REPORTING  ........................................................................ 66 
13.1  Adverse Event Reporting Obligations  ...................................................................... 66 
13.2  Adverse Event Definitions  ........................................................................................ 66 
13.2.1  Pre-Treatment -Emergent Adverse Events  ......................................................... 68 
13.2.2  Laboratory Abnormalities as Adverse Events  ..................................................... 69 
13.3  Severity of Adverse Events  ...................................................................................... 69 
13.4  Classification of Adverse Events by Relationship to Study Drug Administration ....... 69 
13.5  Recording and Reporting Adverse Events  ............................................................... 70 
13.5.1  Recording Adverse Events  ................................................................................. 70 
13.5.2  Investigator Reporting of a Serious Adverse Event  ............................................ 70 
13.6  Additional Investigator Responsibilities on Follow -up of Serious Adverse Events  .... 71 
13.7  Follow -Up of Adverse Events  ................................................................................... 71 
13.8  Notification of Post -Study Serious Adverse Events  .................................................. 72 
13.9  IRB/IEC Notification of Serious Adverse Events  ...................................................... 72 
13.10  Health Authority Safety Reports  ............................................................................... 72 
14 ADMINISTRATIVE ASPEC TS ............................................................................................. 73 
14.1  Investigator Responsibilities for General Study Conduct  ..........................................  73 
14.2  Protocol Deviations  .................................................................................................. 73 
14.3  Subject Information and Consent  ............................................................................. 74 
14.4  Subject Confidentiality and Data Protection  ............................................................. 74 
14.5  Laboratory Accreditation ..........................................................................................  74 
14.6  Required Documents  ............................................................................................... 75 
14.7  Study Monitoring ...................................................................................................... 75 
14.8  Electronic Data Record and Case Report Forms  ..................................................... 75 
14.9  Drug Accountability  .................................................................................................. 76 
14.10  Record Retention  ..................................................................................................... 76 
14.11  Financial Disclosure .................................................................................................  76 
14.12  Investigator’s Final Report  ....................................................................................... 77 
14.13  Publication Policy ..................................................................................................... 77 
14.14  Confidentiality  .......................................................................................................... 78 
15 REFERENCES  .................................................................................................................... 79 
 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   6 of 90 
LIST OF APPENDICES  
Appendix I.  Schedule of Events  ............................................................................................ 82 
Appendix II.  Measurement of Liver Metabolic Function with the Methacetin Breath Test  .......84 
Appendix III.  FibroScan® Protocol  ...........................................................................................86 
Appendix IV.  Diabetes Mellitus Definition and Metabolic Syndrome Criteria ............................88 
 
LIST OF FIGURES  
Figure 1.  Probability of Clinical Decompe nsation in Patients with Cirrhosis with and  
without Clinically Significant Portal Hypertension  ...............................................19 
Figure 2.  Natural History of Cirrhosis: Relationship with Increasing Portal Pressure  .........22 
Figure 3.  Dose -Response Modelling of Emricasan using Biomarkers  ...............................24 
Figure 4.  Study Schema  ...................................................................................................28 
Figure 5.  FibroScan® Probe Placement in Relation to Anatomy of a Subject  ................86 
 
LIST OF TABLES  
Table 1.  Liver Monitoring Procedure ................................................................................36 
Table 2.  Laboratory Tests  ................................................................................................47 
Table 3.  Blood Volume ....................................................................................................49 
Table 4.  Time -Adjusted Incidence Rate for Anticipated Events in Patient Population.......68 
 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   7 of 90 
1 STUDY SYNOPSIS 
Protocol  
IDN-6556- 14 
Title 
A Multicenter, Randomized, Double- Blind, Placebo- Controlled Trial of Emricasan, an Oral 
Caspase Inhibitor, in Subjects with Non -Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe 
Portal Hypertension  
Phase of Trial  
Phase 2  
Objectives 
Primary  Objective  
• To assess whether emricasan compared to placebo leads to a mean decrease in hepatic 
venous pressure gradient (HVPG) at Week  24 in subjects with NASH cirrhosis and 
severe portal hypertension 
Secondary  Objectives 
• To assess the safet y and tolerability of emricasan  
• To characterize the dose response of emricasan on portal pressure as assessed by 
HVPG  at Week  24 
• To assess whether emric asan compared to placebo improves HVPG response at 
Week  24 using a 20% reduction from baseline response definition  
• To assess whether emricasan compared to placebo decreases mechanism specific 
(caspase 3/7) and non- specific alanine aminotransferase (ALT) biomarkers  at Week s 24 
and 48  
Exploratory  Objectives  
• To assess whether emricasan compared to placebo improves HVPG response at 
Week  24 using a 10% reduction from baseline response definition  
• To assess whether emricasan compared to placebo improves liver function and 
prognosis  at Weeks  24 and 48 as assessed by model for end- stage liver disease [1]  and 
Child -Pugh (CP) scores  (change in score, progression, regression)   
• To assess whether emricasan compared to placebo improves biochemical and 
functional biomarkers (cCK18/M30, flCK18/M65, aspartate aminotransferase [ AST], total 
bilirubin, international normalized ratio [ INR], and albumin) at Week s 24 and 48  
• To assess whether emricasan compared to placebo improves fibrosis markers  at 
Week s 24 and 48  
• To assess whether emricasan compared to placebo improves health -related quality of 
life at Week s 24 and 48  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   8 of 90 
• To assess whether emricasan compared to placebo decreases development of 
decompensation or worsening of decompensation at Week s 24 and 48  
• To assess whether emricasan compared to placebo improves liver metabolic function at 
Week s 24 and 48 as assessed by  methacetin breath test (at select sites)  
• To assess whether emricasan compared to placebo improves liver stiffness at Week s 24 
and 48 as assessed by transient elast ography (FibroS can®) (at select sites)  
Centers  
Multicenter, approximately 9 0 sites in North America and Europe  
Number of Subjects  
Approximately 240 subjects (60 subjects/arm) will be randomized in a 1:1:1:1 ratio to emricasan 
50 mg BID, emricasan 25 mg BID, emricasan 5  mg BID , or matching placebo BID.  
Design 
This is a multicenter, double- blind, randomized, placebo- controlled, dose -response study to 
evaluate the safety and efficacy of emricasan in improving portal hypertension in subjects with 
NASH cirrhosis  and severe portal hypertension (defined as HVPG ≥12 m mHg ). Subject s can  
have compensated (at least 6 0% of subjects  but no more than 75% ) or decompensated 
cirrhosis with  no more than 1 prior significant decompensating event and must be currently 
clinically stable  on stable standard therapy  [2] (see Inclusion/Exclusion Criteria ). Randomization 
will be stratified by compensated vs. decompensated status at baseline as well as use of 
non-selective beta- blockers (NSBB) or not . Subjects who are otherwise eligible will undergo the 
HVPG  procedure as the last qualifying procedure prior to Day  1.  
The study treatment duration will be up to 48 weeks , including an initial 24 -week randomized 
treatment phase with follow -up HVPG at Week 24 (primary endpoint) and an additional 24 -week 
treatment phase (continuing the same study drug treatment as initially randomized).   Subjects 
completing the initial 24- week randomized treatment phase will be re- consented for the 
additional 24- week treatment phase.   HVPG measurements will be performed at screening  and 
Week 24, with additional placebo- controlled safety follow -up and exploratory efficacy 
assessments through Week  48.  Subjects will complete a final follow -up visit approximately 
2 weeks after the end of treatment  (i.e., at Week  26 if completing the initial 24-week randomized 
treatment only or at Week 50  if completing the 48 -week treatment ). 
Subjects with baseline HVPG ≥12 mmHg may experience progress ion of cirrhosis  during the 
48-week study.  Given that the primary endpoint for this study is HVPG rather than a clinical 
event (or clinical composite), subjects who have a decompensating event or worsened 
decompensation during the study wi ll not be requir ed to withdraw  and can remain in the study 
unless the invest igator feels the subject is too unstable or the subject requires a transjugular 
intrahepatic portal shunt or other portosystemic bypass procedure, which would confound the 
HVPG assessment . Subject s who  progress  to Child -Pugh C will be withdrawn from study drug 
but are expected to remain in the study and complete all planned study visits  (see 
Section 8.1.7 ).  All subjects who wish to discontinue study dr ug treatment should remain in the 
study and complete all planned study visits, in order to minimize missing data and protect the 
integrity of the study results.  Subjects who withdraw consent for participating in the study 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   9 of 90 
should discontinue study visits.  Subjects for whom the investigator deems that it is not in the 
best interest of the subject to continue participating in the study may also discontinue study 
visits.  
Schema 
 
Dosage and Administration  
Study drug will be double- blind with matching placebo. Emricasan at 50 mg, 25 mg,  or 5 mg or 
matching placebo will be administered orally twice a day.  
Drug Supply  
Emricasan (IDN-6556) and matching placebo will be supplied in bott les containing 60  capsules.  
Subject Entry Criteria  
Inclusion Criteria  
1. Male or female subjects 18 years or older, able to provide written informed consent and able 
to understand and willing to comply with the requirements of the study.  
2. Cirrhosis due to NASH  with exclusion of other causes of cirrhosis (e.g. chronic viral 
hepatitis, alcoholic liver disease, etc.)  
Screening 
Phase
Follow -up 
Phase
HVPG                                           HVPG
Must be ≥ 12 mmHg 
Follow -
up visit
ScreenE
N
D
T
R
E
A
T
M
E
N
T
Emricasan 5 mg BID
N=60
Placebo BID
N=60
Emricasan 50 mg BID
N=60
Emricasan 25 mg BID
N=60R
A
N
D
O
M
I
Z
A
T
I
O
NInitial randomized 
treatment
Double -Blind 
Treatment Phase
Continued 
randomized treatment
Wk-6 to Day 0                          Day 1 -----------Wk24       ----------------Wk48                    -----Wk26 or 50
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   10 of 90 
• Diagnosis of cirrhosis is based on:  
o Biopsy OR  
o Clinical evidence: platelet count < 150,000, AST > ALT, and either nodular liver 
surface on imaging or splenomegaly  
• NASH is based on at least 1 of the following:  
o Prior or current biopsy showing steatohepatitis (fat, ballooning degeneration, 
inflammation) consistent with NASH  
o At least 2 metabolic risk factors for at least 5 years preceding the diagnosis of cirrhosis: diabetes mellitus, impaired fasting glucose, obesity (BMI ≥ 30 kg/m
2 or 
central obesity ), hypertension, dyslipidemia (s ee Appendix IV)  
o Prior or current biopsy showing some but not all diagnostic features of NASH 
(e.g. only fat or ballooning degeneration or inflammation) but with no evidence for 
viral hepatiti s or other liver disease AND either fatty liver disease on prior imaging or 
at least 1 metabolic risk factor (as above) for at least 5 years preceding the diagnosis 
of cirrhosis  
Note:  Previous viral hepatitis that was curatively treated (with sustained vir al 
response) is not an exclusion as long as: 1) viral eradication was achieved at least 3 
years prior to the diagnosis of cirrhosis and 2) all other criteria are met for NASH as 
the etiology of cirrhosis  
3. Compensated cirrhosis  (no history of or presence of clinically evident  ascites, variceal 
hemorrhage,  or encephalopathy , and on no medications to treat  these complications)   
 
OR  
 Decompensated cirrhosis with  no more than 1 prior significant decompensating event : 
a. If prior decompensating ev ent was variceal hemorrhage , event must have occurred at 
least 3 months prior to Day 1 
b. If prior decompensating event was ascites  requiring chronic  diuretics , ascites should be 
well controlled ( not clinically  evident , i.e. no ascites or ascites only detectable by 
ultrasound examination ) on a stable dose of diuretics for  at least 3  months  prior to Day 1  
c. If prior decompensating event was hepatic encephalopathy  ≥ grade II or requiring 
hospitalization, encephalopathy should be well -controlled (St age 0 or 1) on stable 
medication for at least 3  months  prior to Day 1  
Note:  Previous transient ascites or hepatic encephalopathy in a subject who is  currently 
stable without clinically evident ascites or encephalopathy and on no medications for 
these conditions does not count  as a prior s ignificant decompensating event  
4. Severe portal hypertension defined as  HVPG  ≥12 mmHg  (see Section 8.4.1  for 
recommendations to identify subjects more likely to meet the HVPG criteria)  
5. Subjects who are on NSBB, nitrates, diuretics, lactulose, rifaximin, or statins  must be on a 
stable dose for at least 3  month s prior to Day 1  
6. Willingness to utilize effective contraception (for both males and females of reproductive 
potential) from Screening to 4 weeks after the last dose of study drug 
7. Platelet count ≤125 k/mm3 or transient elastography ≥20 kilopascal [3] during screening 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   11 of 90 
8. If on therapeutic dos e of vitamin E, stable for 6 months prior to Day 1  
Exclusion Criteria  
1. Evidenc e of severe decompensation, defined as :  
a. Presence or history of more than one type of significant decompensating event (clinically 
evident ascites requiring chronic diuretics, variceal hemorrhage, and/or overt 
encephalopathy)  
Note : Previous transient ascites or hepatic encephalopathy in a subject who is currently 
stable without clinically evident ascites or encephalopathy and on no medications for 
these conditions does not  count  towards this exclusion (s ee Inclusion Criteria #4).  
b. One type of decompensating event with the following characteristics : 
o More than 1 episode of variceal hemorrhage or bleeding from a portal hypertensive 
source (e.g. portal hypertensive gastropathy)  
o Ascites that has  required more than 1 large -volume paracentesis (>5 L) for treatment 
or that has been complicated by spontaneous bacterial peritonitis, hyponatremia 
(serum Na < 130), and/or hepatorenal syndrome  
o More than 1 episode of overt hepatic encephalop athy requiring hospitalization  
2. Severe hepati c impairment defined as a Child- Pugh score ≥10 
3. ALT >3 times upper limit of normal (ULN) or AST > 5 times ULN during screening  
4. Estimated creatinine clearance <30 mL/min  
5. Prior transjugular intrahepatic portosystemic shunt or other porto- systemic bypass 
procedure  
6. Known portal vein thrombosis  
7. Symptoms of biliary colic, e.g. , due to symptomatic gallstones, within the last 6 months , 
unless resolved following cholecystectomy , other definitive treatment ( e.g., sphincterotomy), 
or medical management (e.g. , ursodeoxycholic acid)  
8. Current use of medications that are considered inhibitors of OATP1B1 and OATP1B3 
transporters : atazanavir, cyclosporine, eltrombopag, gemfibrozil, indinavir, lopinavir, 
ritonavir, ri fampin, saquinavir, simeprevir, telaprevir, tipranovir, or some combination of 
these medi cations  
9. Alpha- fetoprotein > 50 ng/mL 
10. History or presence of clinically concerning cardiac arrhythmias, or prolongation of screening (pre-treatment) QT Interval Corrected by the Fridericia Correction Formula [ QTcF ] interval of 
>500 msec  
11. History of or active malignancies, other than those successfully treated with curative intent 
and believed to be cured  
12. Significant systemic or major illness other than liver disease that i n the opinion of the 
investigator would preclude the subject from participating in and completing the study, 
including but not limited to acute coronary syndrome or stroke within 6 months of screening 
or major surg ery within 3 months of screening 
13. Prior liv er transplant  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   12 of 90 
14. Change in diabetes medications within 3 months of screening, including initiation, 
discontinuation, or change in dose except for medications titrated according to blood 
glucose  
15. Uncontrolled diabetes mellitus (HbA1c >9%)  within 3  months of scr eening 
16. Restrictive bariatric surgery or bariatric device within 1 year of screening or prior 
malabsorptive bariatric surgery  
17. Known human immunodeficiency virus infection 
18. Use of controlled substances (including inhaled or injected drugs) or non -prescribed use of 
prescription drugs within 1 year of screening to the point of interfering with the subject’s 
ability to comply with study procedures and study drug administration in the investigator’s judgement  
19. History of significant alcohol consumption (>20 g/day for females and >30 g/day for males 
on average) within the past 5 years  
20. If female: planned or known pregnancy, positive urine or serum pregnancy test, or 
lactating/breastfeeding 
21. Previous treatment with emricasan or active investigational medication (except  methacetin) 
in a clinical trial within 3 months prior to Day 1  
Criteria for Evaluation  
Safety Variables  
• Adverse events  
• Vital signs, physical examination 
• Laboratory tests ( e.g. chemistry, hematology, coagulation, urinalysis)  
• ECGs  
• Liver and gallbladder events and ultrasound  
Efficacy Variables  
Primary  
• HVPG  mean change from baseline at Week 24 
Secondary 
• HVPG response (20% reduction from baseline)  at Week 24 
• Caspase 3/7 and ALT at Weeks 24 and 48  
Exploratory  
• HVPG response (10% reduct ion from baseline)  at Week 24 
• MELD and Child- Pugh scores , regression, and progression at Weeks 24 and 48 
• cCK18/M30, flCK18/M65, AST, total bilirubin, INR, and albumin at Weeks 24 and 48  
• Fibrosis markers  at Week s 24 and 48  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   13 of 90 
• Health -related quality of life, as measured by Short  Form -36 (SF- 36) and Chronic Liver  
Disease Questionnaire (CLDQ) , at Weeks 24 and 48  
• Clinical outcomes  (development of decompensation or worsening of decompensation)  at 
Weeks 24 and 48  
• Liver metabolic function assessed by m ethacetin breath test (at select s ites) at 
Weeks  24 and 48  
• Liver stiffness by transient elastography (at select sites) at Weeks 24 and 48 
Statistical Methods  
All efficacy analyses will be based on the Full Analysis Set (FAS) and Per Protocol Set .  All 
safety analyses will be based on the Safety Analysis Set.  
The primary endpoint for this study is the change from baseline at Week 24 in HVPG.  The 
change from baseline will be calculated as HVPG at Week 24 minus HVPG at baseline 
(HVPG W24-HVPG BL). Comparisons of the mean change from baseline i n HVPG at Week 24 
between each emricasan treatment group and placebo will be analyzed using a fixed effects 
Analysis of Covariance (ANCOVA) model using the FAS.  This model will include the treatment 
group, compensated vs. decompensated status, and NSBB us e as fixed effects with baseline 
HVPG as a covariate. Least -square adjusted means (LSMeans) will be reported, along with the 
estimated difference in LSMeans  and corresponding 95% confidence intervals . A Dunnett’s test 
will be applied to adjust for the multiple comparisons of each emricasan treatment group with 
placebo.  
Secondary endpoints include the change from baseline at Week s 24 and 48 in Caspase 3/7 and 
ALT measurements  and 20% HVPG response at Week 24.  Exploratory endpoints include 
10% HVPG response at Week 24, change from baseline in MELD and Child- Pugh scores  at 
Weeks 24 and 48, regression/progression in MELD and Child- Pugh scores  at Weeks 24 and 48 , 
biochemical and functional biomarkers  at Weeks 24 and 48 , fibrosis markers at Weeks 24 and 
48, quality of life  at Weeks 24 and 48 , clinical outcome events  at Weeks 24 and 48 , liver 
function at Weeks 24 and 48, and liver stiffness measurements  at Weeks 24 and 48.  
Safety endpoints include treatment compliance, exposure, adverse events, gallbladder adv erse 
effects  and ultrasound, potential drug- induced liver injury, additional laboratory  parameters , vital 
signs, and electrocardiogram measurements.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   14 of 90 
2 LIST OF ABBREVIATION S 
AE Adverse event  
ALT Alanine aminotransferase 
ANCOVA  Analysis of covariance  
AST Aspartate aminotransferase 
AUDIT  Alcohol Use Disorders Identification Test  
BID bis in die, twice daily  
BMI Body mass index  
BUN  Blood urea nitrogen  
cCK18  Caspase- cleaved cytokeratin 18  
CFB Change from baseline  
CFR Code of Federal Regulations  
CI Confidence interval  
CLDQ  Chronic Liver Disease Questionnaire  
cm centimeter  
CP Child -Pugh  
CRF Case report form  
CSPH  Clinically significant portal hypertension  
DILI Drug- induced liver injury  
DMC  Data Monitoring Committee 
ECG  Electrocardiogram  
EDC  Electronic data capture  
EGD  Esophagogastroduodenoscopy  
ELF Enhanced liver fibrosis  
EU European Union  
FAS Full Analysis Set  
FDA US Food and Drug Administration  
FHVP  Free hepatic vein pressure  
flCK18  Full-length cytokeratin 18  
FSH Follicle stimulating hormone 
g gram  
GCP  Good Clinical Practice  
GGT  Gamma glutamyl transferase 
GMP  Good manufacturing practice 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   15 of 90 
HA Hyaluronic Acid  
HbA1c  Glycated Hemoglobin  
HBV Hepatitis B virus  
HCG  Human chorionic gonadotropin  
HCV  Hepatitis C virus  
HDL High density lipoprotein  
HE Hepatic Encephalopathy  
HVPG  Hepatic venous pressure gradient  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
ICMJE  International Committee of Medical Journal Editors  
IEC Independent Ethics Committee  
IMP Investigational medicinal product  
INR International normalized ratio  
IRB Institutional Review Board 
IQR Inter-quartile  
ITT Intention to treat  
IVC Inferior vena cava  
IWRS  Interactive Web Randomization System  
kg Kilogram  
kPa Kilopascal  
L Liter 
LDL Low density lipoprotein  
LOX-L2 Lysyl oxidase- like 2  
LSMeans  Least -square adjusted means  
MBT  Methacetin breath test  
MCS ™ Molecular Correlation Spectrometry  
MedDRA  Medical Dictionary for Regulatory Activities  
MELD  Model for end stage liver disease 
mg Milligram  
mL Milliliter  
mm Millimeter  
mmHg  Millimeter of mercury  
msec(s)  Millisecond(s)  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   16 of 90 
NAFLD  Non- alcoholic fatty liver disease  
NASH  Non- alcoholic steatohepatitis  
ng Nanogram  
NSBB  Non- selective beta- blocker  
OATP Organic anion transporting polypeptide  
P3NP  Aminoterminal propeptide of type III collagen  
PK Pharmacokinetic  
PPS Per Protocol  Set 
PT Prothrombin time 
QOL  Quality of life  
QTcF  QT Interval Corrected by the Fridericia Correction Formula 
SAE Serious adverse event  
SAP Statistical Analysis Plan  
SD Standard deviation  
SF-36 Short Form 36 
SUSAR  Suspected unexpected serious adverse reaction  
TIMP -1 Tissue inhibitor of matrix metalloproteinase 1  
ULN Upper limit of normal  
WBC  White blood cell (count)  
WHVP  Wedged hepatic vein pressure 
YLD Years lived with disability  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   17 of 90 
3 ETHICS  
The study will be conducted in accordance with standards that meet regulations relating to 
Good Clinical Practice (GCP). These include the European Union (EU) Clinical Trials Directive 
(2005/28/EC  and subsequent amendments  and EU Regulation No. 536/2014), International 
Conference on Harmonisation (ICH) Guideline for Good Clinical Practice (GCP) E6, 21CFR 
Part 312, and applicable regulatory requirements.  
The ethical requirements of Institutional Review Boards/Independent Ethics Committees 
(IRB/IECs) and the Informed Consent Forms (ICFs) are discussed in Section 14, Administrative 
Aspects.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   18 of 90 
4 INTRODUCTION 
4.1 BACKGROUND 
Cirrhosis and Portal Hypertension  
Cirrhosis with portal hypertension is a major public health concern. In 2010, cirrhosis was the 
12th leading cause of mortality world- wide, responsible for approximately 1 million deaths 
[4].This estimate was substantiated by the Global Burden of Disease Study 2013, which 
estimated that there were ~1.2 million deaths from cirrhosis in 2013 [5] with an overall 
age-standardized death rate of 18.8/100,000, a rate that is similar in magnitude to all other 
digestive diseases combined (19/100,000), diabetes mellitus (21.6/100,000) and to neoplasms such as colorectal cancer (12.8/100,000) and stomach cancer (13.8/100,000). Interestingly, 
cirrhosis predisposes to and is felt to be largely responsible for the development of 
hepat ocellular carcinoma . If deaths due to hepatocellular carcinoma  from hepatiti s B (300,000), 
hepatitis C (342,500) and alcohol use (92,000) were included in the cirrhosis death estimates, 
the number of deaths would almost double. Thus, cirrhosis and portal hypertension are major 
concerns for public health as well as for patients wit h those diseases.  
Cirrhosis has an important effect  upon morbidity and disability.  The Global Burden of Disease 
Study 2013 [6]  estimated the years lived with disability (YLD) for 301 acute and chronic 
diseases between 1990- 2013 since that is an important input into global and national health 
policies.  Not surprisingly given the high mortality associated with cirrhosis, cirrhosis was an 
important and large contributor to YLDs in 2013, with approximately 3.3 million prevalent cases 
contributing to 545,000 YLDs in 2013.  
Once a patient with chronic liver disease progresses  to cirrhosis  and portal hypertension 
develops (defined as a hepatic venous  pressure gradient [HVPG]  >5 mmHg), survival 
decreases significantly . Cirrhosis consists of at least 2 distinct prognostic stages: compensated 
and decompensated with the development of clinically overt ascites, variceal hemorrhage,  
and/or encephalopathy defining the decompensated stage [7] . When a patient with cirrhosis 
transitions from being “compensated” to “decompensated,” s urvival is markedly decreased. 
While patients with compensated cirrhosi s have a median survival time > 12 years, the median 
survival time for patients wi th decompensated cirrhosis is < 2 years [7-9]. 
Portal hypertension is defined as clinically significant portal hypertension (CSPH) once the 
HVPG is ≥10 mm Hg. In a study of 213 patients with compensated cirrhosis and portal 
hypertension but without varices followed for a median of 51.1 months, those with a baseline HVPG  <10 mmHg had a 90% probability of not progressing to the decompensated state during 
the follow -up period while the risk of decompensation was almost 6 times higher  in the group 
>10 mmHg (unadjusted hazard ratio of 5.7; P<0.001) [10]. Studies indicate t hat mortality 
increases ~3% with every 1 mmHg increase in HVPG , such t hat a patient with an HVPG of 15 
mmHg has a 30% greater risk of death than a patient with an HVPG of 5 mmHg ( Figure 1) [10, 
11]. 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   19 of 90 
Figure 1. Probability of Clinical Decompensation in Patients with Cirrhosis with and 
without Clinically Significant P ortal Hypertension  
 
Solid line : HVPG < 10 mmHg; dotted line: HVPG >10 mmHg  [10]. 
 
CSPH is accompanied with an increased risk for developing hepatic decompensation, including 
bleeding var ices and formation of ascites. Esophageal varices form once the HVPG is 
≥10 mmHg and are present in ~50% of patients with cirrhosis [12] . Variceal bleeding is a 
medical emergency and associated with a 10% to 30% mortality at 6 weeks [2, 7, 12] .  
Importantly, reducing the HVPG to <12 mmHg, or by at least 10- 20%, significantly dec reases 
the risk of variceal bleeding in both primary and secondary prophylaxis settings (for reviews, see [13-15]). 
Patients with CSPH are also at risk for developing ascites. Ascites develops in ~50% of patients 
within 10 years of the diag nosis of cirrhosis [8] . Once ascites is present  (with or without 
esophageal varices ), the mortality rate is approximately 20% per year [7] . Mortality is greater 
when mor e than one complication is present [9]  or when the patient progresses to a st age of 
“further” decompensation characterized by recurrent variceal hemorrhage/encephalopathy, 
refractory ascites,  hyponatremia, and hepatorenal syndrome.  
There is clearly a medical need for a drug that would either decrease the risk for developing 
decompensated cirrhosis in a patient with compensated cirrhosis or for a drug that would 
decrease the risk for a patient with a single decompensating event to develop further decompensation. This drug would result in an impr ovement in survival. In both cases, a d rug 
that could decrease portal hypertension could be reasonably expected to achieve those goals.  

 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   20 of 90 
Standard of Care for Management of Cirrhosis with Portal Hypertension  
There are currently no medications approved for the treatment of cir rhosis or portal 
hypertension. H owever, non- selective beta blockers (NSBB) are the standard of care used in 
clinical practice to prevent variceal bleeding. The American Association for the Study of Liver 
Diseases recommends that NSBB be used in the following clinical settings  [12]: 
• Patients with cirrhosis and small varices that have not bled and who are at higher risk for 
bleeding (Child -Pugh B or C; red w ale marks on Esophagogastroduodenoscopy [ EGD ]) 
• Patients with cirrhosis and medium/large varices that have not bled  
• Patients with cirrhosis who survived an episode of acute variceal hemorrhage  
 
NSBB appear to be effective at decreasing the risk of  bleeding from esophageal varices in 
approximately one- third to one- half of patients [14, 16, 17] . However, bleeding from esophageal 
varices remains a significant clinical problem, even with the use of NSBB. While NSBB 
decrease the risk of variceal bleeding to low levels if the HVPG is lowered below 12 mmHg (~7% bleeding rat e), few patients (less than 15% ) achieve that goal  [7]. For patients with at least 
a 20% reduction in HVPG who do not  achieve an HVPG value <12 mmHg, the risk  of bleeding 
remains substantial  (bleeding rate ~29%) but  is decreased approximately 50%.  Clinically, the 
consequences of a  variceal bleed are important. Variceal bleeding is a medical emergency and 
associated with a 10 -30% mortality at 6 weeks [2, 7, 12] .   
NSBB act by decreasing portal flow but have no effect on  improving intrahepatic circulati on or 
improving liver function. For patients who continue to experience progressive cirrhosis, liver 
transplantation is the only other treatment option. In addition, NSBBs must be used cautiously in 
certain cirrhotic patient populations. For example, propranolol was prospectively shown to 
decrease survival in patients with refractory ascites [18] . These patients often have systemic 
hypotension,  and the Baveno VI consensus conference recommended  that patients with 
refractory ascites should be monitored closely w hen placed on NSBBs and that NSBBs  should 
be reduced or discontinued in the presence of systolic blood pressure below 90 mmHg , 
hyponatremia with a serum sodium below 130 mEq/L , or acute kidney injury  [2]. In addition, 
approximately 15- 20% of patients do not tolerate NSBB  [14, 17] , and another 15% have a 
contraindication to NSBB use [12]. 
4.2 STUDY RATIONALE  
Emricasan  (IDN-6556) is a novel  small molecule irreversible  caspas e inhibitor. Caspases are a 
family of intracellular cysteine protease inhibitors whose function is to mediate apoptosis, a type 
of programmed cell death , and activate some proinflammatory cytokines . Caspases cleave 
cytokeratin- 18, an intracellular structural protein, during apoptosis in a very specific manner to 
produce caspase- cleaved cytokeratin- 18 (cCK18), which is readily detected by a selective and 
commercially available antibody. Some caspases (e.g., caspase- 1) can also process and 
activate pro -inflammatory cytok ines such as interleukin- 1β and interleukin- 18. Caspases 
typically exist as pro- caspases and must be converted to an active form enzymatically. 
Activation of caspases in injured or pre -apoptotic cells leads to cleavage of a number of cell 
proteins, which ultimately results in cell death and activation of some pro- inflammatory 
cytokines. Caspase -mediated apoptotic and inflammatory pathway s have  been previously 
shown to play an important role in liver diseases, leading to the hypothesis that inhibition of 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   21 of 90 
caspases may have significant therapeutic benefit for the treatment of liver fibrosis, independent 
of the underlying disease state (e.g. viral infection, fatty liver, etc .) [19]. Emricasan has been 
shown to be an effective inhibitor of liver injury and inflammation in several  animal models of 
liver disease and to reduce portal hypertension in a model of cholestasis  [20].  
An additional emerging role of caspases is the formation and release of hepatocyte- derived 
microvesicles (also r eferred to as microparticles). Microvesicles are released by virtually all 
cells, but levels are incr eased in some pathologic states and different liver diseases, including 
alcohol, viral infection, and metabolic syndrome. Other processes that increase microvesicle release include oxidative stress, shear stress, systemic inflammation, and bacterial 
translocation.  Many of these processes are present in patients with chronic liver disease, 
especially cirrhosis. Furthermor e, microvesicles are believed to worsen portal hypertension by 
contributing to splanchnic vasodilation, angiogenesis , and vasoconstriction within the liver [21] . 
In support of the notion that caspase inhibition could have a beneficial role in portal 
hypertension, emricasan was recently shown to improve survival and decrease portal pressure 
in a murine model of portal hypertension [20]. Cholestasi s followed by liver injury  was induced 
by ligation of the common bile duct  with resultant increase in portal pressure. Mice received 
either emricasan (10 mg / kg /  day) or placebo for two weeks, with repeat measurement of  portal 
pressure and removal of the liver for histological assessment. Emricasan treatment resulted in 
decreased microparticles and a statistically significant reduction in portal pressure , as well as a 
decrease in fibrosis , although the decrease in fibrosis  did not reach statistical signif icance, 
suggesting that the effects on portal hypertension were at least in part independent of the anti-fibrotic effects of the drug. Importantly , emricasan treatment improved survival.  
In non -cirrhotic patients with chronic liver disease due to two of th e most common etiologies 
(chronic hepatitis C virus [ HCV ] infection and non -alcoholic fatty liver disease [ NAFLD ]), 
emricasan treatment decreased apoptosis biomarke rs and improved transaminases . Emricasan 
treatment was associated with rapid and statistically significant reductions in elevated activ ated 
serum caspases and cCK18  in subjects with chronic HCV [22] . Importantly, emricasan reduced 
cCK18 levels to within the range typical ly observed in healthy subjects, but did not affect c CK18 
levels in healthy subjects  [23], indicating that emricasan can reduce elevated but not basal 
levels of apoptosis. Em ricasan lowered transaminase levels within 1 week and maintained these 
reductions to 12 weeks in patients with chronic HCV infection [24]. Similarly, emricasan 
treatment (at a dose of 25 mg BID) significantly reduced alanine aminotransferase ( ALT) levels  
in subjects with NAFLD and elevated ALT in a 28 -day, placebo- controlled, multi -center  study 
(Study IDN -6556 -06). 
Based on the idea that caspases produce hemodynamically active, proinflammatory 
microparticles from apoptotic cells that could increase portal pressure by increasing intrahepatic 
resistance and/or decreasing splanchnic resistance, a recent open -label pilot study 
(Study  IDN-6556 -11) evaluated whether emricasan (at a dose of 25 mg  twice daily  [BID]) in 
patients with compensated cirrhosis  (primarily due to non- alcoholic steatohepatitis [ NASH ] or 
HCV)  and portal hypertension could lower portal pressure over 28 days. Of 23 subjects enrolled 
with baseline HVPG (5.5 to 32 mmHg), 22 subjects were evaluable for HVPG with data at 
baseline and Day 28.  There was no significant difference in the HVPG response in the overall 
group, but analysis according to the recognized HVPG therapeutic threshold of 12 mmHg 
(indicative of severe portal hypertension) demonstrated a clinically meaningful  mean (standard 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   22 of 90 
deviation [SD]) decrease in HVPG of 3.7 (4.0) mmHg, representing a 17.2% decrease in  the 
group with baseline HVPG ≥ 12 mmHg. Notably, 4/12 had a ≥20% decrease and 8/12 had a 
≥10%  decrease; 2/12 had a decrease in HVPG below 12 mmHg.  Ten subjects with baseline 
HVPG <12  mmHg had a non- significant (p=0.12) mean (SD) increase of 1.9 (3.2) mmHg.  
Emricasan was overall well -tolerated with no drug- related serious adverse events (SAEs) and 
1 subject discontinuing the study early for  non-serious adverse events .  
The reason for a  robust decrease in HVPG in the ≥ 12 mmHg group and lack of discernable 
effect in the < 12 mmHg group could be  related to the differing pathophysiology of portal 
hypertension in these 2 groups.  Figure 2, taken from a clinical review of portal hypertension 
[25], shows that as the HVPG increases to >10 mmHg and patients transition from 
compensated to decompensated cirrhosis, the hyperdynamic circulation becomes an 
increasingly important contributor to portal hypertension.  
Portal hypertension is a dynamic process, and in early portal hypertension (HVPG 6- 10 mmHg), 
the elevated pressures are largely due to increased intrahepatic resistance to blood flow as a 
result of both intrahepatic vasoconstriction and fibrotic changes associated with cirrhosis [26].  
However, as  cirrhosis and portal hypertension progress, splanchnic and systemic vasodilation, 
along with an increased cardiac output, dramatically increase portal venous blood flow [27, 28] . 
These observations explain why NSBBs, which decrease cardiac output and increase 
splanchnic resistance, are ineffective i n patients with early stages of porta l hypertension (HVPG 
<10 mmHg) when increased cardiac output and decreased splanchnic resistance are not yet 
contributing to the portal hypertension in those patients [29-31]. 
Figure 2. Natural H istory of Cirrhosis: Relationship with I ncreasing Portal P ressure 
[25] 
 
Thus, there is sound preclinical and clinical rationale t o believe that  emricasan  can decrease 
HVPG  in subjects with NASH cirrhosis and severe portal hypertension, based on data in 
humans demonstrating the important pathophysiological role of excessive apoptosis and 
inflammation in cirrhosis and portal hypertension, as well as preclinical data showing that 
emricasan decreases apoptosis, inflammation, and fibrosis in mouse models of chronic liver 

 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   23 of 90 
disease, and short -term (~1 month) data in humans with cirrhosis and severe portal 
hypertension demonstrating clinically meaningful reductions in HVPG with emricasan.  
Dose Rationale  
Emricasan has been administered to  624 subjects in 15 completed Phase 1 and 2 studies 
(including 169 healthy subjects, 394 subjects with elevated liver transaminases, 8 subjects with 
severe renal impairment, and 53 liver transplant subjects) with administration of single or 
multiple doses of intravenous or oral emricasan ranging from 0.1  to 10 mg/kg/day intravenously  
or 1 to 500 mg/day orally .  Emricasan has been administered orally  to 510 subjects, including 
383 subjects with liver disease, most of whom received emricasan up to 50 mg BID for up to 
3 months .  Emricasan has generally been well tolerated with most adverse events being mild to 
moderate in se verity, and the most common events (~3-5%) in subjects with liver disease 
receiving oral emricasan being fatigue, nausea, dizziness, and headache, without any clear 
relationship with dose or duration of therapy.  
The relationship between emricasan dose and biomarker responses has been tho roughly 
characterized.  The initial phase 1 and 2 studies assessed the effect of emricasan upon biomarkers at oral doses ranging from 0.5 mg BID up to 200 mg BID.  The 0.5 mg BID dose was 
clearly active, decreasing cCK -18 and ALT by nearly 50%, but had les s effect upon aspartate 
aminotransferase ( AST) and caspase 3/7.  Doses greater than 50 mg BID did not appear to 
have any greater reduction in biomarkers compared to the 50 mg BID dose.  Having therefore 
defined the shape of the dose- response curve, subsequent clinical studies focused on the 5, 25 
and 50 mg BID doses.  
Formal dose- response modeling for emricasan used models based upon reductions of 4 
biomarkers (ALT, AST, cCK18, and caspase 3/7).   Dose response modeling in subjects with 
liver disease predominantly due to HCV who had normal hepatic function indicated that  
emricasan doses >27.6 mg twice daily (BID) provided the greatest probability of leading to 
significant reductions in serum transaminases (reflective of ongoing inflammation) and cCK18 
(reflective of apoptotic activity) ( Figure 3). 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   24 of 90 
Figure 3. Dose -Response Modelling of Emricasan using Biomarkers  
 
 
 
 
The biomarker dose- response curve was relatively flat between 0.5 to 50 mg BID, with doses as 
low as 5 mg BID showing near -maximal reduction for cCK -18 and ALT in subjects with normal 
hepatic function.   Specifically, 5 mg BI D reduced cCK18 and ALT by 71.2% to 83.6% of 
maximal but reduced A ST and caspase 3/7 by only 36.7% to 46.3% of maximal.  The 25 mg 
BID dosed r educed all 4 biomarkers by 74.4% to 96.2% of maximal , and the 50 mg BID showed 
incrementally greater reduction of AST and caspase 3/7.  In addition, studies conducted in 
subjects with hepatic impairment ( IDN-6556- 08 and IDN-6556 -02) suggested that the biomarker 
dose- response curve may be shifted to the righ t with severe hepa tic impairment, and that the 
50 mg dose might more effectively decrease biomarkers in those subjects than the 25 mg 
dose.   Updating the dose response model with biomarker data from subjects with NAFLD 
indicated that the dose response for the NAFLD population was similar to that for the HCV 
population for subjects with elevated transaminases and normal hepatic function.  
While the relationship between dose and biomarker response has been well -characterized, the 
relationship between emricasan dose and clinical responses has not been thoroughly assessed.  Understanding that relationship is an important goal of the proposed phase 2b study.  Pilot 
studies conducted only with the 25 mg BID dose of emricasan showed that this dose lowered 
portal vein pressures (HVPG) in subjects with severe portal hypertension following 1 month of 
treatment, and improved model for end stage liver disease [1] scores in subjects with baseline 
Dose 
(mg BID ) 
% of maximum response  
CK-18 
 ALT 
 AST 
 Caspase 3/7  
5 
 83.6 
 71.2 
 46.3 
 36.7 
15 
 93.9 
 88.1 
 72.1 
 63.5 
25 
 96.2 
 92.5 
 81.2 
 74.4 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   25 of 90 
MELD scores ≥15 following 3 mont hs of treatment and provided the rationale to further explore 
the safety and efficacy of emricasan in patients with cirrhosis.  To better understand the shape 
of the dose -response curve for clinically important endpoints (HVPG and MELD score) in 
subjects w ith cirrhosis and hepatic impairment (Child- Pugh classes A and B), the Sponsor 
intends to study the 5, 25 and 50  mg BID doses of emricasan.  
Thus, the 5, 25, and 50 mg BID doses proposed for this Phase 2 study were chosen to evaluate 
a dose that is anticipated to be active but likely sub- maximal (5 mg BID) as well as a dose with a 
high likelihood of maximal efficacy based upon the biomarker dose- response curve (50 mg 
BID), with inclusion of an intermediate dose (25 mg BID) that has demonstrated efficacy on HVPG and MELD score in prior studies.   This approach is reasonable given the large number of 
subjects exposed to repeat oral doses as high as 200 mg BID, good safety profile to date, lack 
of identified drug- related toxicities, and lack of tolerability issues at doses less than 500 mg (at 
which transient, mild GI symptoms were reported).  Animal toxicology studies identified the 
gallbladder and intestines as having the potential for toxicity.  However, careful assessment of 
pre- and post -dosing gallbladder ul trasound examinations and analysis of safety data for 
adverse events potentially related to either gallbladder or intestinal inflammation has revealed 
no evidence for a safet y concern in humans to date.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   26 of 90 
5 STUDY OBJECTIVES  
The objectives of this study are:  
Primary Objective  
• To assess whether emricasan compared to placebo leads to a mean decrease in hepatic 
venous pressure gradient ( HVPG ) at Week  24 in subjects with NASH cirrhosis and 
severe portal hypertension 
Secondary Objectives 
• To assess the safety and tolerability of emricasan  
• To evaluate the dose response of emricasan on portal pressure as assessed by HVPG  
at Week  24 
• To assess whether emricasan compared to placebo improves HVPG response at 
Week  24 using a 20% reduction from baseline response definition  
• To assess whether emricasan compared to placebo decreases mechanism specific (caspase 3/7) and non- specific (ALT) biomarkers at Weeks  24 and 48  
Exploratory Objectives  
• To assess whether emricasan compared to placebo improves HVPG  response at 
Week  24 using a 10% reduction from baseline response definition  
• To assess whether emricasan compared to placebo improves liver function and 
prognosis at Weeks  24 and 48 as assessed by model for end- stage liver disease [1]  and 
Child -Pugh (CP) scores (change in score, progression, regression)  
• To assess whether emricasan compared to placebo improves biochemical and 
functional biomarkers (cCK18/M30, flCK18/M65, AST, total bilirubin, INR, and albumin) 
at Weeks  24 and 48  
• To assess whether emricasan compared to placebo improves fibrosis markers  at 
Weeks  24 and 48  
• To assess whether emricasan compared to placebo improves health -related quality of 
life at Weeks  24 and 48  
• To assess whether emricasan compared to placebo decreases development of decompensation or worsening of decompensation at Weeks  24 and 48  
• To assess whether emricasan compared to placebo improves liver metabolic function at 
Weeks  24 and 48 as assessed by methacetin breath test (at select sites)  
• To assess whether emricasan compared to placebo improves liver stiffness at Weeks  24 
and 48 as assessed by transient elastography (FibroS can
®) (at select sites)  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   27 of 90 
6 STUDY DESIGN  
This is a multicenter, double- blind, randomized, placebo- controlled, dose -response study to 
evaluate the safety and efficacy of emricasan in improving portal hypertension in subject s with 
NASH cirrhosis and severe portal hypertension (defined as HVPG ≥12 mmHg). Subjects can 
have compensated  (at least 6 0% of subjects  but no more than 75% ) or decompensated 
cirrhosis with  no more than 1 prior significant decompensating event and must be currently 
clinically stable on stable standard therapy  [2] (see Inclusion/Exclusion Criteria ). Randomization 
will be stratified by compensated vs. decompensated status at baseline as well as use of 
non-selective beta- blockers (NSBB) or not. Subjects who are otherwise eligible will undergo the 
HVPG procedure as the last qualifying procedure prior to Day 1. 
The study treatment duration will be up to 48 weeks , including an  initial 24 -week randomized 
treatment phase with follow -up HVPG at Week 24 (primary endpoint) and an additional 24 -week 
treatment phase (continuing the same study drug treatment as initially randomized) .  Subjects 
completing the initial 24- week randomized treatment phase will be re- consented for the 
additional 24- week treatment phase.  HVPG measurements will be performed at screening and 
Week 24, with additional placebo controlled safe ty follow -up and exploratory efficacy 
assessments through Week 48.  Subjects will complete a final follow -up visit approximately 
2 weeks after the end of treatment  (i.e., at Week  26 if completing the initial 24-week randomized 
treatment only or at Week 50 if completing the 48 -week treatment ). 
Subjects with baseline HVPG ≥12 mmHg may experience progression of cirrhosis  during the 
48-week study.  Given that the primary endpoint for this study is HVPG rather than a clinical 
event (or clinical composite), subjects who have a decompensating event or worsened decompensation during the study will not be required to withdraw and can remain in the study 
unless the investigator feels the subject is not stable or the subject requires a transjugular 
intrahepatic portal shunt or other portosystemic bypass procedure, which would confound the 
HVPG assessment . Subject s who  progress  to Child -Pugh C will be withdrawn from study drug 
but are expected to remain in the study and complete all planned study visits (see 
Section 8.1.7 ).  All subjects who wish to discontinue study drug treatment should remain in the 
study and complete all planned study visits, in order to mi nimize missing data and protect the 
integrity of the study results.  Subjects who withdraw consent for participating in the study 
should discontinue study visits.  Subjects for whom the investigator deems that it is not in the 
best interest of the subject to continue participating in the study may also discontinue study 
visits.  
Subjects will be randomized in a 1:1:1:1 ratio to emricasan 50 mg BID, emricasan 25 mg BID, emricasan 5 mg BID or matching placebo BID.  
For each subject, the study will consist of:  
• Screening period of up to 6 weeks  
• Double-blind treatment period of 24 or 48 weeks  
• A follow -up visit 2  weeks after the Week 24 or Week 48 (or early termination) visit  
 
The duration of each subject’s participation will be approximat ely 32 or 56 weeks.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   28 of 90 
Figur e 4. Study Schema 
 
 
Appendix I, Schedule of Events*, indicates which procedures and evaluations will be performed 
throughout  the study.  An overview of key events is described below.  
Screening Phase (Week - 6 to Day 0)  
Subjects will undergo a Screening period of up to 6 weeks; however, the screening could be 
completed within a shorter time frame.  Subjects will sign an ICF before  any study -related 
procedures are performed. Subjects will be screened t o determine their eligibility. 
Medical/surgical history, medication record (prior and concomitant medications and therapy), 
and a physical examination including vitals will  be obtained for all subjects. A series of 
laboratory and diagnostic tests will be performed. In general, a qualifying HVPG  should be the 
last assessment performed during the Screening phase prior to randomization and should only 
be performed in subjects who meet all other eligibility  criteria.  
                                                
*If any discrepancies should be found between the text of the protocol and Appendix I, Schedule of Events, the table 
will predominate.  
Screening 
Phase
Follow -up 
Phase
HVPG                                           HVPG
Must be ≥ 12 mmHg 
Follow -
up visit
ScreenE
N
D
T
R
E
A
T
M
E
N
T
Emricasan 5 mg BID
N=60
Placebo BID
N=60
Emricasan 50 mg BID
N=60
Emricasan 25 mg BID
N=60R
A
N
D
O
M
I
Z
A
T
I
O
NInitial randomized 
treatment
Double -Blind 
Treatment Phase
Continued 
randomized treatment
Wk-6 to Day 0                          Day 1 -----------Wk24       ----------------Wk48                    -----Wk26 or 50
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   29 of 90 
Initial 24 -Week Double -Blind T reatment Phase (Day 1 to Week 24 ) 
All subjects will be evaluated regularly through study visits  every 4 weeks  and laboratory and 
diagnostic  tests for safety a nd efficacy as described in Appendix I, Schedule of Events.  
Continued 24 -Week Double- Blind Treatment Phase (Week 25 to Week 48)  
Subjects consenting for continued treatment (cont inuing the same study drug treatment as 
initially randomized) will be evaluated regularly through study visits every 8 weeks  and 
laboratory and diagnostic tests for safety and efficacy as described in Appendix I, Schedule of  
Events. Subjects can be seen more frequently for clinical reasons if indicated,  but study 
assessments do not need to be performed at visits that are  solely for clinical care.  
Follow -up Phase (Approximately 2 weeks after W eek 24 or Week 48 ) 
Subjects will return approximately 2  weeks after completing Week 24 or Week 48 for a follow -up 
visit (either at Week 2 6 or Week 50). The visit will include  study assessments as specified in t he 
Schedule of Events.  This is the final  study visit for all subjects. The end of the trial will be when 
the last subject completes the last follow -up visit.  
All subjects who prematurely discontinue the study, regardless of the cause, should undergo a 
follow-up visit (see Section 8.7.1 ) approximately 2 weeks following the early discontinuation 
visit.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   30 of 90 
7 STUDY  POPULATION  
7.1 INCLUSION CRITERIA  
To participate in this study, subjects must meet all  of the following criteria:  
1. Male or female subjects 18 years or older, able to provide written informed consent and able 
to understand and willing to comply with the requirements of the study.  
2. Cirrhosis due to NASH with exclusion of other causes of cirrhosis (e.g. chronic viral 
hepatitis, alcoholic liver disease, etc.)  
• Diagnosis of cirrhosis is based on:  
o Biopsy OR  
o Clinical evidence: platelet count < 150,000, AST > ALT, and either nodular liver 
surface on i maging or splenomegaly  
• NASH is based on at least 1 of the following:  
o Prior or current biopsy showing steatohepatitis (fat, ballooning degeneration, inflammation) consistent with NASH  
o At least 2 metabolic risk factors for at least 5 years preceding the diagnosis of cirrhosis: diabetes mellitus, impaired fasting glucose, obesity ( Body Mass Index 
(BMI) ≥30 kg/m
2 or central obesity), hypertension, dyslipidemia (See Appendix IV)  
o Prior or current biopsy showing some but not all diagnostic features of NASH 
(e.g. only fat or ballooning degeneration or inflammation) but with no evidence for 
viral hepatitis or other liver disease AND either fatty liver disease on prior imaging or 
at least 1 metabolic risk factor (as above) for at least 5 years preceding the diagnosis 
of cirrhosis  
Note:  Previous viral hepatitis that was curatively treated (with sustained viral response) is 
not an exclusion as long as: 1) viral eradication was achieved at least 3 years prior 
to the diagnosis of cirrhosis and 2) all other criteria are met for NASH as the 
etiology of cirrhosis  
3. Compensated cirrhosis (no history of or presence of clinically evident ascites, variceal 
hemorrhage, or encephalopathy, and on no medications to treat these complications)   
OR  
 Decompensated cirrhosis with no more than 1 prior significant decompensating event : 
a. If prior decompensating event was variceal hemorrhage, event must have occurred at 
least 3 months prior  to Day 1  
b. If prior decompensating event was ascites requiring chronic diuretics, ascites should be 
well controlled (not clinically evident , i.e. no ascites or ascites only detectable by 
ultrasound examination ) on a stable dose of diuretics for at least 3  months  prior to Day 1  
c. If prior decompensating event was hepatic encephalopathy ≥ grade II or requiring hospitalization, encephalopathy should be well -controlled (Stage 0 or 1) on stable 
medication for at least 3  months  prior to Day 1  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   31 of 90 
Note:  Previous transient ascites or hepatic encephalopathy in a subject who is currently 
stable without clinically evident ascites or encephalopathy and on no medications 
for these conditions does not count  as a prior significant decompensating event  
4. Severe portal hypertension defined as HVPG ≥12 mmHg  (see Section 8.4.1  for 
recommendations to identify subjects more likely to meet the HVPG criteria)  
5. Subjects who are on NSB B, nitrates, diuretics, lactulose, rifaximin, or statins must be on a 
stable dose for at least 3  month s prior to Day 1  
6. Willingness to utilize effective contraception (for both males and females of reproductive 
potential) from Screening to 4 weeks after the last dose of study drug 
7. Platelet count ≤125 k/mm3 or transient elastography ≥20 kilopascal [3] during screening 
8. If on therapeutic dose of vitamin E, stable for 6 months prior to Day 1  
7.2 EXCLUSION CRITERIA  
Subjects who meet any of the following criteria will be excluded from the study:  
1. Evidence of severe decompensation, defined as:  
• Presence or history of more than one type of significant decompensating event (clinically 
evident ascites requiring chronic diuretics, variceal hemorrhage, and/or overt encephalopathy)  
Note:  Previous transient ascites or hepatic  encephalopathy in a subject who is currently 
stable without clinically evident ascites or encephalopathy and on no medications 
for these conditions does not count towards  this exclusion 
(See Inclusion  Criteria  #4). 
 
• One type of decompensating event with t he following characteristics : 
• More than 1 episode of variceal hemorrhage or bleeding from a portal hypertensive 
source (e.g. portal hypertensive gastropathy)  
• Ascites that has required more than 1 large -volume paracentesis (>5 L) for treatment or 
that has been complicated by spontaneous bacterial peritonitis, hyponatremia (serum 
Na <130), and/or hepatorenal syndrome  
• More than 1 episode of overt hepatic encephalopathy requiring hospitalization 
 
2. Severe hepati c impairment defined as a Child- Pugh score ≥10  
3. ALT >3 times upper limit of normal (ULN) or AST > 5 times ULN during screening  
4. Estimated creatinine clearance <30 mL/min  
5. Prior transjugular intrahepatic portosystemic shunt or other porto- systemic bypass 
procedure  
6. Known portal vein thrombosis  
7. Symptoms of biliary colic, e.g. due to symptomatic gallstones, within the last 6 months , 
unless resolved following cholecystectomy , other definitive treatment (e.g. , sphincterotomy), 
or medical management (e.g. , ursodeoxycholic acid)  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   32 of 90 
8. Current use of medications that ar e considered inhibitors of OATP1B1 and OATP1B3 
transporters : atazanavir, cyclosporine, eltrombopag, gemfibrozil, indinavir, lopinavir, 
ritonavir, rifampin, saquinavir, simeprevir, telaprevir, tipranovir, or some combination of 
these medications  
9. Alpha- fetop rotein > 50 ng/mL 
10. History or presence of clinically concerning cardiac arrhythmias, or prolongation of screening 
(pre-treatment)  QT Interval Corrected by the Fridericia Correction Formula (QTcF ) interval of 
>500 msec  
11. History of or active malignancies, other  than those successfully treated with curative intent 
and believed to be cured  
12. Significant systemic or major illness other than liver disease that in the opinion of the 
investigator would preclude the subject from participating in and completing the study,  
including but not limited to acute coronary syndrome or stroke within 6 months of screening 
or major surgery within 3 months of screening 
13. Prior liver transplant  
14. Change in diabetes medications within 3 months of screening, including initiation, 
discontinuation, or change in dose except for medications titrated according to blood 
glucose  
15. Uncontrolled diabetes mellitus (HbA1c >9%)  within 3  months of screening 
16. Restrictive bariatric surgery or bariatric device within 1 year of screening or prior 
malabsorptive bariatric surgery  
17. Known human immunodeficiency virus infection 
18. Use of controlled substances (including inhaled or injected drugs) or non -prescribed use of 
prescription drugs within 1 year of screening to the point of interfering with the subject’s 
ability to comply with study procedures and study drug administration in the investigator’s judgement  
19. History of significant alcohol consumption (>20 g/day for females and >30 g/day for males 
on average) within the past 5 years  
20. If female: planned or known pregnancy, positive urine or serum pregnancy test, or 
lactating/breastfeeding 
21. Previous treatment with emricasan or active investigational medication (except methacetin)  
in a clinical trial within 3 months pri or to Day 1  
7.3 SUBJECT IDENTIFICATI ON 
During the screening period, subjects will be identified by a unique screening number composed 
of the 3 -digit site number and a 2 -digit subject identification number that starts with 01.   On 
Day 1, subjects who will be randomized will be identified by a unique 4 -digit randomization 
number.   Only qualified subjects will be assigned a randomization number.  
7.4 RANDOMIZATION PROCEDURE  
The assignment to emricasan or placebo will be performed randomly. The randomization 
schedule wi ll be generated using a validated randomization program and verified for accuracy 
using strict quality control procedures.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   33 of 90 
The assignment of randomization number and treatment assignment will be centrally 
coordinated through the study’s Interactive Web  Randomization System (IWRS).  
Randomization numbers will be assigned by the IWRS.  The IWRS will not ify sites when 
enrollment for compensated subjects reaches 75 % or enrollment for decompensated subjects 
reaches 40% . 
The randomization will be stratified by  2 factors:  
• Compensated vs. decompensated status at baseline 
• Use of non- selective beta- blockers (NSBB) or not  
7.5 BLINDING/UNBLINDING PROCEDURES  
Investigators will be able to unblind subjects through the IWRS when it is medically imperative to know whether a s ubject is receiving emricasan or placebo, such as in the event of an adverse 
event (AE) that the Investigator feels cannot be adequately treated without knowing the identity of the study drug.   Every effort must be made to contact the Medical Monitor to di scuss the case 
before breaking the blind, or if in an emergency, as soon as possible thereafter (no later than 
24 hours after emergency unblinding) to inform the Medical Monitor  that unblinding was 
performed but without disclosing the actual treatment assi gnment .  Investigator should make 
arrangements to ensure that access to the secure internet site (i.e.,  individual user name and 
password) is maintained in strict confidence to prevent a compromise of subject blinding by 
non-study or unauthorized individua ls.  
The Sponsor may access the randomization codes for subjects with potential suspected unexpected serious adverse reactions (SUSARs) for the purpose of regulatory reporting or for 
the purpose of evaluating an emergent safety issue.   In such an event, th e Sponsor will 
document the rationale, circumstances, and the person or persons being informed about the 
unblinding.  
If the blind for a subject is broken (by the Investigator or the Sponsor), an entry must be made in the electronic data capture system that  contains the reason that the blind was broken and the 
name of the person contacted at the Sponsor or designee.   If the Investigator becomes 
unblinded to a subject’s study drug assignment, the subject should be withdrawn from the study.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   34 of 90 
8 STUDY  ASSESSMENTS A ND CONDUCT  
8.1 SAFETY ASSESSMENTS 
8.1.1  Adverse Events  
Adverse events verbatim terms will be collected at each study visit.  The start date of the event, 
stop date of the event (if known), severity, relationship to study drug (emricasan or placebo) or 
to methacetin,  seriousness, outcome, and action taken for each verbatim term will also be 
collected.  All verbatim terms will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA ) dictionary for purposes of summarization.  AEs (except SAEs, see Section 13.8) 
should be collected for a subject starting from signing of the informed consent until the subject’s 
last study visit (follow -up visit, early  termination, or last regularly scheduled study visit).  
8.1.2  Medical History and Physical Examinations  
Medical  and surgical  history will be taken at screening .  A comprehensive physical examination 
will be performed at the Screening,  Week 24, and Week  48 visits including examination of :  
general appearance, skin, head, eyes, ears, nose, throat, neck (including thyroid), lymph nodes, 
chest, heart, abdomen (including liver and spleen examination), ex tremities, and nervous 
system. A focused physical examination lim ited to relevant assessments and based on any 
symptoms or concerns related to a particular body system will be performed at all other visits. 
Weight, assessed in street clothes  with shoes and outerwear off,  and height (screening visit 
only) will be recorded at the specified visits. Each subject’s body mass index (BMI) will be 
calculated. Assessment of Child -Pugh clinical fe atures will be performed at all visits. 
8.1.3  Vital Sign Measurements 
Respiratory rate, pulse, systolic and diastolic blood pressure, and temperature measurements 
(‘vital signs’) will be performed. Evaluation of the respiratory rate will be measured by counting 
the inhalations for one minute. Blood pressure and heart rate measured during the HVPG 
procedure will also be collected.  
8.1.4  12-Lead Electrocardiogram (ECG)  
A 12-lead ECG will be performed at Screening and at subsequent visits, as specified in the 
Schedule of Events.  Original ECGs with interval printouts and rhythm strips  run at 25 mm/sec 
must be provided as source documentation.  
Automatically calculated QTc intervals will be reviewed and checked for gross  inaccuracies by 
the Investigator or designated ECG reviewer.  If clinically significant findings occur as 
determined by the Investigator, the Medical Monitor should be contacted.   
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   35 of 90 
8.1.5  Monitoring for Potential Gallbladder Adverse Effects  
Due to pre- clinical findings that emricasan was associated with gallbladder inflammation, 
specific safety evaluation and monitoring procedu res will be followed.  
• Subjects with symptoms of biliary colic, e.g. due to symptomatic gallstones, within the 
last 6 months , unless resolved following cholecystectomy,  other definitive treatment 
(e.g., sphincterotomy), or medical management (e.g. , ursodeoxycholic acid), will be 
excluded from the study.  
• All subjects will have a comprehensive liver and gallbladder ultrasound (including 
examination of the biliary tree, assessment of whether gallbladder wall thickening is present, and measurement of gallbladder wall thickness) at the Screening visit, unless 
the subject had an ultrasound within 3 months of Screening that captures all the 
assessments noted above.  If source documentation is provided, the prior ultrasound 
can be used in p lace of the Screening ult rasound .  An anonymized copy of the report  
(and images if needed) from the ultrasound (whether historical or performed for the 
study)  should be provided to the Sponsor.  
• At each study visit, the Investigator will specifically assess the subject for any symptoms consistent with biliary colic , e.g. sharp right upper quadrant pain, nausea, vomiting, fever 
(with cholecystitis), etc . If the subject reports symptoms of biliary colic or other 
symptoms suggestive of gallbladder disease on directed questioning or  spontaneously 
reports such symptoms at any other time during the study, a follow -up liver and 
gallbladder ultrasound (including assessment of the biliary tree and any gallbladder abnormalities) should be performed.  If additional ultrasounds (or other ima ging)  are 
performed during the study for evaluation of biliary colic, assessment of the gallbladder as noted above should be performed, and an anonymized copy of the report(s) (and 
images if needed) should be provided to the Sponsor .   
• Symptoms of biliary colic  or other symptoms suggestive of gallbladder disease (such as 
cholecystitis ) that trigger a follow -up ultrasound should be recorded as  AEs that are  
possibly or probably related to study drug.  
8.1.6  Monitoring for Evidence of Potential Drug -Induced Liver Inj ury (DILI)  
Liver transaminases (ALT, AST) and total bilirubin will be monitored regularly (assessed at each 
study visit) during the study not only as mechanism -independent biomarkers of inflammation, 
but also for any evidence of potential DILI .  Given that  the patient population to be studied has 
underlying liver disease and therefore is likely to have abnormalities in liver transaminases 
and/or bilirubin at baseline, the guidelines for DILI monitoring in this study have been adapted 
from the US Food and Dr ug Administration ( FDA) guidance on DILI that was based primarily on 
monitoring subjects with normal liver enzymes and bilirubin at baseline and incorporate 
suggestions provided to the Sponsor from the FDA regarding monitoring for DILI in subjects 
who have abnormal baseline values of liver transaminases and/or total bilirubin.  
 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in 
Subjects with Non -Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   36 of 90 
Table 1. Liver Monitoring Procedure 
 Additional Monitoring ONLY  Additional Monitoring AND Study Medication Interruption  
Criteria  If any ONE of the following 2 criteria are met:  
• Isolated increase in ALT or AST and minimal or no increase in 
total bilirubin (TB) in the absence of clinical hepatitis 
symptoms  (including but not limited to fever, anorexia, nausea, 
vomiting, abdominal pain, rash)  
o ALT >2x baseline if baseline ALT >2x ULN OR  
o ALT >3x ULN if baseline ALT ≤2x ULN OR  
o AST >2x baseline if baseline AST >2x ULN OR  
o AST >3x ULN if baseline AST ≤2x ULN  
o No increase in TB greater than criteria below  
• Isolated increase in TB and minimal or no increase in ALT or 
AST in the absence of clinical hepatitis symptoms (as described 
above)  
o TB >2x baseline if baseline TB >ULN OR  
o TB >2x ULN if baseline TB ≤ULN  
o No increase in ALT or AST greater than criteria above If any ONE of the following 6 criteria are met:  
• Isolated transaminase increase 
o ALT OR AST > 8x ULN  
• Increase in TB that is related to an increase in direct bilirubin 
(defined as a direct bilirubin to TB ratio >35%)  
o TB increase >2.0 mg/dL if baseline TB >2.0 mg/dL OR  
o TB >2x baseline or >1.5x ULN, whichever is higher, if 
baseline TB ≤2.0 mg/dL  
• Increases in transaminases and TB  
o ALT >3x baseline if baseline ALT >ULN OR   
o ALT >5x ULN if baseline ALT ≤ULN OR 
o AST >3x baseline if baseline AST >ULN OR   
o AST >5x ULN if baseline AST ≤ULN  
AND  
o TB >2x baseline if baseline TB >ULN OR  
o TB >2x ULN if baseline TB ≤ULN  
• Increase in cholestatic marker (ALP) when the ALP increase is 
due to a hepatic source 
o ALP >2x baseline if baseline ALP >ULN OR  
o ALP >3x ULN if baseline A LP ≤ULN  
• Increase in INR that is refractory to vitamin K administration in the absence of a clear reason (e.g. initiation of anticoagulants 
that can affect INR)  
o INR increase of >0.4 if baseline INR >ULN OR  
o INR increase to >1.5 if baseline INR ≤ULN  
• Any incr ease in transaminases or TB if associated with 
symptoms (e.g., fever, anorexia, nausea, vomiting, abdominal 
pain, rash) and/or >5% eosinophilia  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in 
Subjects with Non -Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   37 of 90 
Confirmation 
of Need for 
Additional 
Liver Monitoring  If either of above criteria met: 
• Repeat liver profile (AST, ALT, total and direct bilirubin, GGT, 
alkaline ph osphatase, albumin, CBC, and INR) within 2 to 3 
days to confirm the elevation 
o If a subject lives in a remote area, use of local labs may be 
approved by the Sponsor  
o The Investigator will ensure that loc al lab results are 
promptly reviewed  
• If not confirmed, resume routine laboratory testing  If any of above criteria met:  
• Repeat liver profile (AST, ALT, total and direct bilirubin, GGT, 
alkaline ph osphatase, albumin, CBC, and INR) within 2 to 3 
days to confi rm the elevation 
o If a subject lives in a remote area, use of local labs may be 
approved by the Sponsor  
o The Investigator will ensure that local lab results are promptly reviewed  
• If not confirmed, resume routine laboratory testing  
Study 
Medication 
Interruption  Not applicable  If elevated tests confirmed: 
• Interrupt study medication  
Work -up for 
Liver Injury  If elevated tests confirmed: • Initiate work -up for other causes of liver injury (see below)  If elevated tests confirmed: 
• Initiate work -up for other causes of liver injury (see below)  
Close 
Monitoring  If elevated tests confirmed:  
• Monitor the subject with laboratory testing 2 or 3 times weekly with the frequency of testing decreased to once a week or less 
if abnormalities stabilize and the subject is asymptom atic  
o If a subject lives in a remote area, use of local labs may be 
approved by the Sponsor  
o The Investigator will ensure that local lab results are promptly reviewed  
• Discontinue frequent lab monitoring and resume usual study 
visit monitoring schedule when  
o ALT and AST decrease to <1.2x baseline (or <1.2x ULN if 
baseline value <ULN) on two consecutive measurements  
o TB decreases to <1.3x baseline (or <1.3x ULN if baseline value <ULN) on two consecutive measurements  
• Clinical judgment should determine the intensity and duration of 
close monitoring for subjects who are clinically stable and 
asymptomatic but with elevated test(s)  If elevated tests confirmed:  
• Monitor the subject with laboratory testing 2 or 3 times weekly with the frequency of testing decreased to once a week or less 
if abnormalities stabilize and the subject is asymptomatic   
o If a subject lives in a remote area, use of local labs may be approved by the Sponsor  
o The Investigator will ensure that local lab results are promptly reviewed  
• Discontinue fr equent lab monitoring and resume usual study 
visit monitoring schedule when  
o ALT, AST, ALP decrease to <1.2x baseline (or <1.2x ULN if baseline value <ULN) on two consecutive measurements  
o TB, INR decreases to <1.3x baseline (or <1.3x ULN if baseline value <ULN) on two consecutive measurements  
• Clinical judgment should determine the intensity and duration of 
close monitoring for subjects who are clinically stable and/or 
asymptomatic but with elevated test(s)  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in 
Subjects with Non -Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   38 of 90 
Potential 
Restart of 
Study 
Medication after 
Interr uption  Not applicable  
• In accordance with the FDA “Guidance for Industry Drug 
Induced Liver Injury (DILI): Premarketing Clinical Evaluation”  
o If a subject has suspected DILI, restarting study medication 
is NOT recommended 
• If DILI is considered unlikely AND l iver tests return to levels 
indicated above for discontinuing close monitoring  
o Restarting study medication may be considered according to 
the discretion of the Investigator and after discussion with 
the Sponsor  
Follow -up 
During Restart 
of Study 
Medication  
after 
Interruption  Not applicable  • Laboratory tests (as noted above for confirmatory testing) 
should be checked within 2 -3 days after restarting study 
medication, followed by weekly lab tests for 2- 4 weeks 
(depending on Investigator judgment) and then mont hly for 3 
months, which may occur at regular study visits  
• Any subject who meets the criteria for liver monitoring (after 
confirmatory testing) a second time will have study medication 
permanently  discontinued  
 
If elevated tests are confirmed, the following work -up should be performed at the first monitoring visit:  
• Obtain a more detailed history of symptoms and prior and concurrent diseases  
• Obtain further history of concomitant drug use (including non -prescripti on medications, herbal and dietary supplement 
preparations), alcohol use, recreational drug use, and special diets  
• Obtain a history for exposure to environmental chemical agents and travel  
• Obtain serology for viral hepatitis (hepatitis A immunoglobulin M [ IgM], HBV surface antigen, HCV antibody, hepatitis E IgM,  
cytomegalovirus IgM, Epstein Barr virus antibody panel) and autoimmune hepatitis (e.g. anti -nuclear antibody)  
• Perform further testing for Gilbert’s if appropriate (e.g. if total bilirubin is elevated )  
 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non -Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   39 of 90 
8.1.7  Management of  Subjects Who Progress to Child- Pugh C  
Subjects with Child- Pugh C status at baseline will be excluded. Child- Pugh status will be 
assessed at each visit during the study, and subjects who progress  to Child -Pugh C will be 
considered for withdrawal  from study  drug treatment . However, given the day to day fluctuations 
in clinical laboratory parameters (total bilirubi n, albumin, INR) that could trans iently change a 
subject’s Child -Pugh status to C, a Child- Pugh C score should be confirmed on repeat testing 
and evaluation before withdrawing study  drug treatment .  Laboratory tests and clinical 
evaluation consistently con firming Child -Pugh C status should lead to study drug withdrawal.  
Subjects should, however, remain in the study and complete all scheduled study visits .   
If post -baseline Child- Pugh score is ≥ 10 
• Subject should return for repeat laboratory testing (total bilirubin, albumin, INR) and 
clinical evaluation (ascites, hepatic encephalopathy) ideally within 3 days of the tests 
consistent with Child- Pugh C status but at least within 7 days  
o If repea t Child -Pugh score (2nd test) is <10, the subject should continue study drug 
treatment with the next follow -up occurring at the next regularly scheduled study visit .  
o If repeat Child -Pugh score (2nd test)  is ≥11, the subject should be withdrawn from 
the study drug,  but should complete all scheduled study visits.  
o If repeat Child -Pugh score (2nd test)  is 10 and the investigator feels the subject is 
clinically stable to continue study  drug treatment , the subject should return for repeat 
laboratory testing (total bilir ubin, albumin, INR) and clinical evaluation (ascites, 
hepatic enc ephalopathy) in 1- 2 weeks  
 If repeat Child -Pugh score (3rd test) is  ≥10, the subject should be withdrawn from 
the study  drug, but should complete all scheduled study visits.  
 If repeat Child- Pugh score (3rd test) is <10, the subject should continue study 
drug treatment with the next follow -up occurring at the next regularly scheduled 
study visit . 
8.1.8  Screening and Follow -up Questionnaires for Alcohol Abuse  
The Alcohol Use Disorders Identification Test (AUDIT) is a 10 -item questionnaire developed to 
screen for excessive drinking, helping to identify whether a person has hazardous (or risky) 
drinking, harmful drinking, or alcohol dependence.  The AUDIT- C is a 3 -question version of 
AUDIT that performed similarly to the full AUDIT for detecting heavy drinking and/or active 
abuse or dependence [32] . 
The Skinner Alcohol Dependence scale is a 25 -item questionnaire that provides a quantitative 
measure of the severity of alcohol dependence, with scores in the 1st, 2nd, 3rd, and 4th quartiles 
corresponding to low, intermediate, substan tial, and severe levels of al cohol dependence being 
likely.  
The AUDIT and Skinner Alcohol Dependence scale will be used during Screening to screen for any evidence of alcohol abuse, and the AUDIT -C will be used during the treatment phase of the 
study to monitor for any evidence of active alcohol abuse.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non -Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   40 of 90 
8.1.9  Screening Esophagogastroduodenoscopy (EGD)  
An EGD will be performed during screening , unless the subject had a prior  EGD performed 
within an acceptable time frame according to the recommendations  outlined in the Baveno VI 
Consensus Workshop on portal hypertension [2], and records from the prior EGD are available.  
For example, if there is ongoing liver injury (e.g. NASH), patients with compensated cirrhosis 
with no varices on screening EGD should h ave surveillance endoscopy at 2- year intervals while 
patients with decompensated cirrhosis and small varices should have surveillance endoscopy at 
1-year intervals. Subjects with medium  or large varices or with decompensated cirrhosis should 
have surveillance endoscopy at 1- year intervals.   
The following information should be available from the EGD: presence or absence of esophageal var ices, size of varices (small, medium, large), and any high -risk stigmata (e.g. red 
wale signs).  Small varices are defined as those that barely protrude above the esophageal 
mucosa but that persist after air insufflation of the esophagus, large varices are  those that 
occupy half of the esophageal lumen, and medium -sized varices are those that are intermediate 
between small and large.  
If the Investigator deems it medically necessary, additional EGDs other than those specified by 
the protocol may be performed  during the study.  If additional EGDs are performed during the 
study, the reasons for and results of the additional EGDs w ill be captured as study data.  
8.2 EFFICACY ASSESSMENTS  
8.2.1  Hepatic Venous Pressure Gradient (HVPG)  
The HVPG is the difference between wedged (or occluded) hepatic vein pressure (WHVP) and 
free hepatic vein pressure (FHVP) and represents the gradient between the portal vein and the 
intra-abdominal inferior vena cava (IVC) pressure , with normal HVPG being 3-5 mmHg. It is a 
measure of intrahepati c sinusoidal pressure that correlates directly with direct measurements of 
portal pressure in cirrhosis.  
Measurement of the HVPG is a moderately invasive procedure that involves insertion of a catheter via the right internal jugular vein to measure WHVP and FHVP. The WHVP is obtained 
by inflating a balloon at the tip of the catheter to occlude the lumen of the hepatic vein 
(preferably the main right hepatic vein) . The FHVP is obtained by deflating the balloon of the 
hepatic vein catheter and is very close to the IVC pressure. If the diffe rence between FHVP and 
IVC is ≥ 2 mmHg, this usually reflects the catheter advanced t oo far into the hepatic vein. The 
FHVP shoul d be obtained with the catheter tip 1 -3 cm into the hepatic vein; if the point of 
adequate balloon occlusion is further down the hepatic vein, FHVP should be repeated at this "withdrawn" position. The WHVP and FHVP are affected equally by intra- abdominal pressure 
(e.g. increased intra- abdominal pressure in ascites), whereas their gradient (HVPG)  is not. 
Therefore, the measurement of HVPG incorporates its own zero reference point and is not 
affected by increases in intra -abdominal pressure. Furthermore, the use of the HVPG eliminates 
another very important source of error, the external zero reference point, whic h should be 
placed at the level of the mid- axillary line and kept constant during the study . 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non -Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   41 of 90 
Practical C onsiderations for HVPG Measurement  
• The procedu re is an outpatient procedure (median duration of ~25 minutes) that is 
generally well -tolerated and usually associated with minimal complications (mostly 
hematoma and/or pain at site of puncture).  
• WHVP can also be measured by advancing the catheter into t he smallest branch of the 
hepatic vein and “wedging” it, but this is less accurate than the “occluded” pressure 
because the balloon catheter occludes a larger hepatic venous branch and can, 
theoretically, measure WHVP over a wider vascular territory of the  liver compared with a 
wedged catheter.  
• The test  should be performed preferably i n the morning because there is  circadian 
variation of the HVPG (higher during the day, lower at night) .  For a given subject, the 
Screening and Week 24 tests should be perfor med at approximately the same time of 
the day , i.e. after fasting in the morning.  
• The test  should be performed after an overnight fast as the HVPG increases after food 
ingestion (1 -2 hours post -prandial), particularly in cirrhosis.   
• The procedure may be d one under slight conscious sedation with intravenous 
midazolam, but deep sedation (e.g. wi th opioids such as fentanyl) must  be AVOIDED  as 
it can lead to artifacts caused by  exaggerated deep breathing.    
• At least three sets of WHVP (with continuous recording at least 60 sec [or longer if the 
pressure is still increasing] ) and FHVP (with recording at least 20 -30 sec) measurements 
should be collected, with the average used to calculate the final HVPG result.  
• Adequate occlusion of the hepatic vein should be checked by injecting a small amount 
(0.5 mL) of contrast dye with the balloon inflated.  
• After the WHVP and FHVP measurements are obtained, 3 additional pressure measurements should be collected as the cathet er is being withdrawn (and without 
interrupting the recording): a) at the most proximal portion of the hepatic vein (juncture 
between IVC and hepatic vein), at the IVC (at the level of the hepatic vein) and at the 
right atrium.  
 
HVPG will be performed at Screening and Week 24 visits. A b lood sample from the hepatic vein 
and a paired systemic sample (obtained from the jugular vein through the side arm of the venous introducer) will be collected for measurement of biomarkers.  
Generally, the HVPG should be t he last assessment performed during the Screening phase 
prior to randomization and should only be performed in subjects who fulfill all other inclusion criteria. A central reader appointed for this study will ensure that all participating sites are 
quali fied to perform the procedure. Original tracings of the pressure measurements will be kept 
at the site as part of source documentation for the study, and redacted copies will be forwarded 
to the Central Reader for evaluation. A manual providing more details on the HVPG procedure 
will be provided to sites.  
8.2.2  Model for End Stage Liver Disease [1]  Score 
The Model for End- Stage Liver Disease, or MELD , is a scoring system for assessing the 
severity of chronic liver disease and short -term mortality .  An earlier version of the formula for 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non -Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   42 of 90 
MELD used the subject's values for serum bilirubin, serum creatinine, and the international 
normalized ratio (INR) for prothrombin time and was calculated according to the following 
formula (rounded to the nearest whole number ): 
Previous MELD =  3.78[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] 
+ 9.57[Ln serum creatinine (mg/dL)] + 6.43  
 
If the patient was  dialyzed  twice within the last 7 days, then the value for serum creatinine used 
was set to  4.0. Any value less than 1 was given a value of 1 (i.e. if bilirubin was 0.8, a value of 
1.0 was used) to prevent the occurrence of scores below 0 (the natural logarithm  of 1 is 0, and 
any value below 1 would yield a negative result).  
In January 2016, the Organ Procurement and Transplantation Network  updated the MELD 
score to include sodium for the purpose of liver organ allocation.  Thus, th e MELD score is now 
calculated based on the previous  MELD score (provided above)  as well as  sodium (Na) 
according to the following formula (which will be the one used for the purpose of this study) : 
MELD = previous MELD + 1.32 × (137- Na) – [0.033 × previous MELD × (137-Na)] 
 
Sodium values <125 mmol/L will be set to 125, and values >137 mmol/L will be set to 137.  
8.2.3  Child -Pugh Score and Classification  
The Child -Pugh s core (sometimes referred to as the Child- Turcotte -Pugh score) is used to 
assess the prognosis of chronic liver disease and is calculated as the sum of five component 
scores. Tot al bilirubin, serum albumin, prothrombin time , ascites, and hepatic encephalopathy 
components are scored with values of 1 to 3 points with 3 indicating the greatest severit y.  This 
provides a Child- Pugh s core of 5 to 15 points.  The Child- Pugh score is used to determine the 
Child -Pugh classification  (A, B, or C).  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non -Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   43 of 90 
Parameter  Child -Pugh  Score  
1 2 3 
Total B ilirubin (mg/dL)  <2.0 2.0-3.0 >3.0 
Albumin (g/dL)  >3.5 2.8-3.5 <2.8 
Ascites  Currently  with no 
ascites or ascites only 
detectable on imaging 
(grade 1) and not  on 
diuretics  Currently  ascites only 
detectable on imaging 
(grade 1) and treated 
with diuretics OR with overt ascites (grade 2 
or 3) that is  diuretic 
responsive  Currently  with overt 
ascites (grade 2 or 3) 
that is not diuretic 
responsive  
Hepatic Encephalopathy  
(HE) Currently  with no overt 
HE and not  on specific 
therapy * Currently  with no overt 
HE and no asterixis on 
treatment  with specific 
therapy OR currently  
with grade 2 HE 
(confused but talking 
and/or with asterixis) 
not on treatment with 
specific therapy  Currently  with grade 2 
HE despite treatment 
with specific therapy or 
currently  with grade 3 
HE or grade 4 HE  
Prothrombin time (sec prolonged)  or INR  <4 
(INR < 1.7) 4-6 
(INR 1.7 -2.3) >6 
(INR >2.3)  
 
Child -Pugh Classification  Child -Pugh Score  
Child -Pugh A  5-6 
Child -Pugh B  7-9 
Child -Pugh C  10-15 
8.2.4  Quality of Life Assessments  
Health -related quality of life ( QOL) will be assessed by using the Short Form 36 (SF -36) and 
Chronic Liver Disease Questionnaire (CLDQ ). 
The SF -36 is a generic, validated, widely used QOL assessment survey that has shown good 
psychometric properties in div erse disease states, including patients with advanced liver 
disease. The SF- 36 consists of 36 questions that make up 8 subscales (physical function, 
physical role limitation, bodily pain, general health, vitality, social function, emotional role 
limitation , and mental health) with 0 as the worst and 100 as the best possible score.  An overall 
physical health score and mental health score are derived from the subscale scores.  Norm -
based scoring involves a linear transformation to transform scores to a mean of 50 and standard 
deviation of 10, such that a score > 50 is interpreted as better health than t he US population, 
and a score < 50 means poorer health.  In 713 subjects with NAFLD (61% of whom had definit e 
NASH) enrolled in the NASH Clinical Research Networ k, those with NAFLD had worse physical 
and mental health scores compared with the US population with and without chronic illness, and 
those with NASH had lower physical health compared w ith NAFLD subjects without NASH [33]. 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non -Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   44 of 90 
The CLDQ  was developed to assess health -related QOL in patients with chronic liver disease 
[34] and includes 29 questions in 6 domains: fatigue, activity, emotional function, abdominal 
symptoms, systemic symptoms, and worry.  Patients  found the CLDQ clear and easy to 
complete in 10 minutes.  The CLDQ correlated with disease severity, showing a gradient 
between patients without  cirrhosis, patients with Child -Pugh A cirrhosis, and patients with 
Child -Pugh B or C cirrhosis  [34].  In a study of 237 patients with chronic liver disease related to 
NAFLD, chronic HCV, or chronic hepatitis B virus ( HBV), NAFLD patients had significant ly lower 
quality of life scores compared to HCV and HBV patients on multiple CLDQ domains [35]. 
8.2.5  Clinical Outcome Events 
Clinical outcome events  are an efficacy measure and will be defined based on whether the 
subject has  compensated cirrhosis or decompensated cirrhosis at study entry, and for the latter, 
depending on what the prior decompensating event was.  Subjects may have more than 
1 clinical outcome event. Subjects who have compensated cirrhosis on study entry and have a 
decompensating event could meet criteria for an additional decompensating event(s) if they 
remain in the study.  All clinical outcome events should be reported as AEs. An event reflecting 
progression of chronic liver disease that meets criteria for being adverse but does not qualify as a clinical outcome event (e.g. worsening ascites not requiring paracentesis)  should s till be 
reported as an AE.  
Baseline (Day 1)  
Cirrhosis S tage Decompensating E vent Prior to 
Day 1  Qualifying Clinical Outcome E vents  
Compensated  Not applicable  • New onset clinically evident ascites  
requiring chronic diuretics  
• Variceal hemorrhage  
• New onset  overt  hepatic encephalopathy  
requiring hospitalization  
Decompensated  Ascites, not clinically evident (no 
ascites or only detectable by 
ultrasound)  on a stable dose of 
diuretics  • Variceal hemorrhage  
• Worsening ascites requiring paracentesis  
• New onset overt hepatic encephalopathy  
requiring hospitalization  
Decompensated  Prior variceal hemorrhage  • Recurrent  variceal hemorrhage  
• New onset clinically evident ascites  
requiring chronic diuretics  
• New onset  overt  hepatic encephalopathy  
requiring hospitalization  
Decompensated  Hepatic encephalopathy, 
currently with no or mild 
encephalopathy (Stage 1) on 
lactulose  and/or rifaximin • Variceal hemorrhage  
• New onset clinically evident ascites 
requiring chronic diuretics  
• Worsening overt hepatic encephalopathy 
requiring another  hospitalization  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non -Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   45 of 90 
8.2.6  Liver Metabolic Function by Methacetin Breath Test  
The 13C-methacetin breath test (MBT) is a noninvasive tool to assess liver microsomal capacity 
to metabolize the nonradioactive 13C-labeled Methacetin. The Breath Test System consists of 
the BreathID® Molecular Correlation Spectrometry ( MCSTM) device and a test kit containing a 
breath collection nasal cannula and a nonradioactive isotope 13C-methacetin solution. The 
BreathID MCS device measures and computes the 13CO 2/12CO 2 ratio in the subject’s exhaled 
breath in real time.   Additional details for the procedure are provided in Appendix II. 
The BreathID MCS device is based on an FDA -approved device (510k#: K130524) for 
assessment of Helicobacter pylori infection in the stomach utilizing 13C-urea as a substrate. As 
a standalone device, it is classified by the FDA as Class I, which means that for general use, 
the device is exempt from pr e-marketing application. The MBT, which consists of both a device 
and an unapproved drug component, is however considered an investigational devic e. 
Performance and safety of the device utilizing the 13C-methacetin substrate for assessment of 
liver function have been studied in thousands of subjects worldwide, including in a large US 
pivotal study (G080107) enrolling over 400 subjects with chronic l iver disease from 
11 participating sites (including 141 subjects with biopsy proven cirrhosis). This study 
demonstrated an excellent safety profile of the MBT. Furthermore, there are currently 2 ongoing 
MBT studies for detection of clinically significant portal hypertension in subjects with advanced 
liver disease and for assessment of correlation to severity of liver disease in subj ects with 
NAFLD.  
Subjects will be asked to sit in a chair with a nasal cannula (a small tube) attached to the 
BreathID MCS devi ce placed inside their nostrils while breathing normally.  The BreathID  MCS 
device w ill measure  the subject’s baseline carbon dioxide production for approximately 
10 minutes (up to 25 minutes), after which the subject will be administered 1 cup of a soluti on of 
a 75 mg Methacetin pre- dissolved in water. Methacetin is exclusively broken up in the liver and 
turns into carbon dioxide and acetaminophen. The subject will remain sitting in a chair with the 
nasal cannula in their nose breathing in a normal fashion for another 60 minutes while the 
BreathID  MCS device measures carbon dioxide production. Additional details on the procedure  
as well as the parameters obtained from the MBT are  provided in Appendix II. 
The MBT will be perform ed at select sites  at Screening , Week 24, and Week  48. MBT should be 
performed within 1 week of HVPG but not within 24 hours after HVPG. If MBT is performed on 
the same day as the HVPG test, it should be performed before the HVPG test. For the Week 24 
and Week 48 MBT , subjects should take their morning dose of study drug prior to the test. Sites 
who elect to participate in the MBT measurements  will perform the test at the specified visits for 
all subjects enrolled at their site.  
8.2.7  Liver Stiffness by T ransient Elastography ( using FibroScan®) 
Transient elastography  is a non-invasive,  reproducible method for measuri ng liver stiffness that 
correlates with liver fibrosis and will be measured using F ibroScan® (manufacturer Echosens) .  
An ultrasound  transduc er probe is mounted  on the axis of a vibrator;  vibrations  of mild amplitude 
and low frequency are transmitted by the transducer, induci ng a wave that propagates throu gh 
the under lying tissue.  The propa gation velocity of the wave  is then measured. The veloci ty is 
directly related to tissue  stiffness; the stiffe r the tissue, the faster the wave propag ates.  The 
protocol for the FibroScan® procedure is provided in Appendix III. 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non -Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   46 of 90 
Transient elastography  measurements will be performed at select sites  at Screening , Week  24, 
and Week  48. Sites who elect to participate in the transient elastography  measurements will 
perform the test at the specified visits for all subjects enrolled at their site.  
8.3 LABORATORY TESTS  
Blood and urine collected for laboratory tests will be analyzed according to standardized, 
validated assays.  The central  laboratory will  supply detailed instructions and all necessary 
containers for blood and urine collections.  Blood and urine sample volumes should meet the 
laborator y’s specification.   
Table 2 presents the laboratory tests t o be performed during the study for screening purposes 
and safety and efficacy evaluations , including routine chemistry, hematology  (complete blood 
count with automated differential) , coagulation, and urinalysis.    
Metabolic  
Given the significant association of cirrhosis with insulin resistance and components of the 
metabolic syndrome (especially fasting plasma glucose and blood pressure) [36], particularly for 
patients with NASH, metabolic parameters will be evaluated in the study including fasting plasma glucose, HbA1c, lipid levels (total cholesterol, high density lipoprotein ( HDL) cholesterol, 
low density lipoprotein ( LDL) cholesterol, triglycerides), and insulin resistance.  Insulin 
resistance will be estimated using a commonly used index based on fasting insulin and glucose 
called the homeostasis model assessment  of insulin resistance  (HOMA -IR), which provides a 
measure of hepatic insulin resistance [37]. 
Fibrosis Markers  
The Enhanced Liver Fibrosis (ELF) panel is based on 3 serum markers (hyaluronic acid [HA], 
aminoterminal propeptide of type III collagen [P3NP], and tissue inhibitor of matrix metall oproteinase 1 [TIMP -1]) and has demonstrat ed utility in predicting advanced fibrosis in 
patients with chronic liver disease related to NAFLD [38] , chronic HCV infection [39] , and 
alcoholic liver di sease [40].  In addition, a study of 457 patients with chronic liver disease 
followed for a median of 7 years demonstrated that the ELF test predicted clinical liver -related 
outcomes  [41]. Ferritin is a component of several scores (based on clinical parameters and lab 
tests) that have demonstrated utility in predicting fibrosis  [42]. Lysyl ox idase- like 2 (LOX -L2) is 
an enzyme expressed in the liver that is responsible for crosslinking collagen and consequently 
stabilizing it to degradation.  LOX -L2 activity is an indicator of f ibrosis and has recently 
demonstrated utility in predicting clinically significant portal hypertension [43].  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non -Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   47 of 90 
Table 2. Laboratory Tests  
Hematology & 
Coagulation  Chemistry  Urinalysis  Metabolic  Research  Other  
Hemoglobin  
Hematocrit  
RBC count  
Platelet count  
WBC count  
Neutrophils  
Eosinophils  
Monocytes  
Basophils  
Lymphocytes  
MCV, MCH, 
MCHC, MPV  
Peripheral smear
1 
 
INR, PT, PTT BUN, Creatinine,  
Creatinine 
clearance 
(Cockcroft -Gault),  
Ca, Na, K, Cl,  
Phosphorus, Mg, 
Total CO 2 
(Bicarbonate),  
AST2, ALT2, 
Total bilirubin, 
Direct bilirubin  
Alkaline 
phosphatase,  
Uric acid, 
Albumin,  
Total protein,  
Globulin, LDH,  
GGT, Glucose  
 
serum β -HCG and 
urine pregnancy 
test3 
 
DILI 
Confirmation 
(as needed)  
• ALT, AST , 
Total and 
direct 
bilirubin, GGT, alkaline 
phosphatase, 
albumin, 
CBC, INR pH 
Glucose (qual)  
Protein (qual)  
Blood (qual)  
Ketones  
Microscopy4 
 
Protein5 
(quantitative)  
Creatinine5 
(quantitative)  Hemoglobin A1c  
 Lipid Panel  
• Total 
cholesterol  
• LDL 
• HDL 
• Triglycerides  
 
Fasting insulin, 
HOMA -IR
6 Fibrosis  
Markers  
ELF Panel  
(Hyaluronic acid , 
P3NP, TIMP -1) 
Ferritin  
LOX-L2 
 
Peripheral and 
HVPG 
Biomarkers  
Caspase 3/7  
cCK18  
flCK18  
 
Population PK  
including back -
up Etiologic screen7 
• HBsAg  
• Anti-HCV Ab8 
• Ferritin, transferrin 
saturation ( calculated from 
iron, TIBC, UIBC)  
• Ceruloplasmin  
• ANA 
• α1-antitrypsin  
 α–fetoprotein
7 
 
Transporter genotyping  
 
DILI Monitoring (as  needed)  
First visit after confirmation  
• ALT, AST, Alkaline 
phosphatase, INR, Total  
and direct  bilirubin , GGT, 
albumin, CBC  
• HAV IgM, HBsAg, 
Anti-HCV antibody8, HEV 
IgM, CMV IgM  
• EBV panel (VCA -IgM, 
VCA-IgG)  
• Autoimmune hepatitis  
(ANA, SMA, anti -LKM1)  
• Testing for Gilbert’s, as 
needed  
Additional visits (as needed)  
ALT, AST, Alka line 
phosphatase , INR, Total  and 
direct  bilirubin , GGT, 
albumin, CBC 
Abbreviations: ANA=antinuclear antibody; anti -LKM1=anti -liver kidney  microsomal type 1 antibody;  CBC=complete blood count; 
CMV=cytomegalovirus;  CO 2=carbon dioxide;  EBV=Epstein -Barr virus;  HAV = hepatitis A virus; HBsAg = hepatitis B surface 
antigen; HEV=hepatitis E virus; LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; MCHC=mean corpuscular 
hemoglobin concentration; MCV=mean corpuscular volume; MPV=mean platelet volume; PTT=parti al thromboplastin time; 
RBC=red blood cell ; SMA=smooth muscle antibody;  TIBC =total iron binding capacity ; UIBC=  unsaturated iron binding capacity ; 
VCA-IgG=viral capsule antigen immunoglobulin G; VCA -IgM=viral capsule antigen immunoglobulin M  
1 Lab to complete automatically if necessary  
2 A second test for ALT and AST is required during Screening at least 2 weeks from the first draw  
3 For females of reproductive potential 
4 Only if urine dipstick is positive for blood or protein  
5 At Screening and Day 1, with subsequent tests as needed (e.g. for evaluation of hepatorenal syndrome)  
6 Calculated by the central laboratory  
7 At screening only  
8 If positive, Hep C confirmation to be completed  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non -Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   48 of 90 
8.3.1  Biomarker Assessments 
Peripheral blood samples will be obtained according to the Schedule of Events. The following 
serum biomarkers will be assessed  by the central laboratory : caspase 3/7, cCK18/M30, 
flCK18/M65. An aliquot will be stored until the end of the study and then test ed for  
microparticles . In addition, effects on biomarkers of mechanism of action and inflammation may 
be measured.  
In addition to collection of peripheral blood samples, 2 blood samples will be collected a t the 
time of the HVPG test : a hepatic vein sample, and a paired systemic sample obtained from the 
jugular vein. For the HVPG samples, the central laboratory will test  caspase 3/7, cCK18/M30, 
and flCK18/M65. Aliquots from the HVPG samples will be stored until the end of the study and 
then tested for microparticles, coagulation biomarkers , bacterial translocation biomarkers, and 
hepatic vasculature function biomarkers . Samples will  be destroyed once all analyses are 
completed.   
Samples should be processed for serum and plasma, divided into the central laboratory -
specified number of aliquots (including back -ups), and frozen at - 70 °C or colder.   Samples 
should be shipped on dry ice to the central laboratory.  
8.3.2  Population Pharmacokinetic (PK) Assessment  
Samples will be obtained according t o the Schedule of Events for population pharmacokinetic 
assessment . After processing, sample s should be equally divided into 2 aliquots  and frozen 
at -70 °C or colder.  Samples should be shipped on dry ice to the central laboratory . One aliquot 
will be  forwarded to MicroConstants for analysis , and one will be stored at the central laboratory  
for re -testing if needed.  Samples will be destroyed once all analyses are  completed.  
8.3.3  OATP Transporter Genotyping 
The role of genetic variants of OATP1B1 and OATP1B3 transporters on the hepatic uptake of 
emricasan and their effect on the pharmacokinetics and pharmacodynamics of emricasan is 
currently not well understood. Genetic polymorphism(s) can play an important role in the 
pharmacokinetics and pharmacodynamics of  many  drugs. If the subject provides consent, a 
blood sample will be collected on Study Day 1 to evaluate each subject’s OATP transporter genetic variants.   Samples will be shipped to the central laboratory  and then to Gentris for 
testing . Samples will be destroyed once all analyses are completed.  
8.3.4  Blood Volume  
The total blood sampling volume for an individual subject is approximately 2 31 mL for subjects 
who complete the initial 24- week randomized treatment only and 306 mL for subjects who 
complete the 48- week randomized treatment, as shown in Table 3.  
 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in 
Subjects with Non -Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   49 of 90 
Table 3. Blood Volume  
Sample Type  Sample 
Volume 
(mL)  Number of Samples Per Study Phase  24-Week 
Treatment  48-Week 
Treatment  
Screening  Treatment  
Follow -Up Total 
Volume 
(mL)  Total 
Volume 
(mL)  Initial 24  Weeks  Continued 24  Weeks  
Hematology  2 1 7 3 1 18 24 
Chemistry  6 1 7 3 1 54 72 
Coagulation  3 1 7 3 1 27 36 
Fibrosis markers  8 0 2 1 0 16 24 
Lipids1 - 0 2 1 0 - - 
Insulin  2 0 2 1 0 4 6 
HbA1c  2 0 2 1 0 4 6 
Etiologic screen  10 1 0 0 0 10 10 
α-fetoprotein  2 1 0 0 0 2 2 
Serum pregnancy test 1, 2 - 1 1 0 0 - - 
Population PK  6 0 6 3 0 36 54 
Biomarkers – peripheral 
blood  4 1 7 3 1 36 48 
Biomarkers (plasma) – 
HVPG samples (hepatic 
vein, systemic)  4 1 1 0 0 8 8 
Biomarkers (serum) – 
HVPG samples (hepatic 
vein, systemic)  4 1 1 0 0 8 8 
OATP transporter 
genotyping  6 0 1 0 0 6 6 
Second screening liver 
tests  2 1 0 0 0 2 2 
TOTAL  231 306 
1 Drawn as part of chemistry panel  
2 For females of reproductive potential only  
Note : Additional blood samples may be taken at times specified by the Sponsor or the Investigator (or due to sample/test repeat).  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   50 of 90 
8.4 SPECIFIC STUDY VISIT INFORMATION  
The following sections provide specific details of the assessments to be performed at each 
study visit as noted in the Schedule of Events:  
8.4.1  Screening Phase (Week - 6 to Day 0)  
The following study evaluations will be performed during the course of the Screening phase:  
• Signed informed consent  
• Eligibility criteria (inclusion and exclusion criteria)  
• Medical and surgical history  
• Assessment for adverse events, including biliary colic symptoms  
• Review of c urrent medications including prescription and nonprescription drugs, 
vitamins, and dietary supplements  
• Comprehensive physical examination including vital signs, height, weight  
• Assessment of Child -Pugh clinical features   
• 12-lead ECG  
• Screening questionnaire s for alcohol dependence: AUDIT, Skinner  
• Clinical laboratory evaluations: chemistry, hematology, coagulation, urinalysis, etiologic  
screen, α-fetoprotein, serum pregnancy test (for females of reproductive potential)  
o AST, ALT, and total and direct bilirubin should be measured twice during the 
screening phase (at least 2  weeks apart)  
• Blood sample for biomarkers  
• Liver and gallbladder ultrasound  
• Esophagogastroduodenoscopy  
• HVPG , including collection of hepatic vein and systemic blood samples  
• Methacetin breath t est (at select sites)   
• FibroS can® (at select sites)  
 
In general, the HVPG  should be performed after the subject meets all other eligibility criteria.   To 
identify subjects more likely to meet the HVPG ≥ 12 mmHg criteria, it is recommended (but not 
required) that subjects have one of the following prior to having the HVPG test:  
1. History or presence of medium or large varices  
2. Evidence of collateral circulation on imaging 
3. History of ascites  
8.4.2  Double- Blind Phase (Day 1)  
• Confirmation of eligibility criteria  
• Review concomitant medications and other therapies (vitamins and dietary supplements)  
• Assessment for adverse events, including biliary colic symptoms  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   51 of 90 
• Focused physical examination, v ital signs, weight , assessment of Child -Pugh clinical 
features  
• Questionnaires: SF-36, Chronic Liver Disease Questionnaire  
• Clinical laboratory evaluations  (after fasting at least 10 hours ): chemistry, hematology,  
coagulation,  urinalysis, metabolic parameters (insulin, lipids, HbA1c), fibrosis markers, 
serum and urine p regnancy test s (for females of reproductive potential)  
• Blood samples for biomarkers and OATP transporter genotyping 
• Study drug dispensation 
 
The study procedures specified for Day 1 should be performed prior to dosing with study drug.  
8.4.3  Double- Blind Phase (W eek 4)  
• Review concomitant medications and other therapies (vitamins and dietary supplements)  
• Assessment for adverse events, including biliary colic symptoms  
• Study drug compliance assessment  
• Focused physical examination, v ital signs, weight , assessment of Child -Pugh clinical 
features  
• 12-lead ECG  
• Clinical laboratory evaluations: chemistr y, hematology, coagulation, urinalysis, urine  
pregnancy test (for females of reproductive potential ) 
• Blood samples for biomarkers and population PK  
• Study drug dispensation 
8.4.4  Initial 24 -Week Double -Blind Phase (Week 8, Week 12, Week 16, Week 20)  
• Review concomitant medications and other therapies (vitamins and dietary supplements)  
• Assessment for adverse events, including biliary colic symptoms  
• Study drug compliance assessment  
• Focused physical examination, v ital signs, weight , assessment of Child -Pugh clinical 
features  
• Ques tionnaire: AUDIT- C (Week 12  only)  
• Clinical laboratory evaluations: chemistry, hematology, coagulation, urinalysis, urine 
pregnancy test (for females of reproducti ve potential)  
• Blood samples for biomarkers and population PK  
• Study drug dispensation 
8.4.5  Initial 24 -Week Double -Blind Phase (Week 24)  
• Review concomitant medications and other therapies (vitamins and dietary supplements)  
• Assessment for adverse events, including biliary colic symptoms  
• Study drug compliance assessment  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   52 of 90 
• Comprehensive physical examination, v ital signs, weight , assessment of Child- Pugh 
clinical features  
• 12-lead ECG  
• Questionnaires: SF -36, Chronic Liver Disease Questionnaire, AUDIT -C 
• Clinical laboratory evaluations  (after fasting at least 10 hours ): chemistry, hematology, 
coagulation, urinalysis, fibrosis markers, metabolic parameters (insulin, lipids, HbA1c), 
urine pregnancy test (for females of reproductive potential)  
• Blood samples for biomar kers and population PK  
• HVPG , including collection of hepatic vein and systemic  blood samples  
• Methacetin breath test (at select sites)  
• FibroS can® (at select sites)  
• Signed informed consent  (for subjects who signed consent  for the second 24- week 
treatment  phase only)  
• Study drug dispensation ( for subjects who signed consent  for the second 24- week 
treatment  phase only) 
8.4.6  Continued 24 -Week Double- Blind Phase (Week 32 and Week  40) 
• Review concomitant medications and other therapies (vitamins and dietary supplement s) 
• Assessment for adverse events, including biliary colic symptoms  
• Study drug compliance assessment  
• Focused physical examination, v ital signs, weight, assessment of Child- Pugh clinical 
features  
• Clinical laboratory evaluations: chemistry, hematology, coagul ation, urinalysis, urine 
pregnancy test (for females of reproductive potential)  
• Blood samples for biomarkers and population PK  
• Study drug dispensation 
8.4.7  Continued 24 -Week Double- Blind Phase (Week 48)  
• Review concomitant medications and other therapies (vitami ns and dietary supplements)  
• Assessment for adverse events, including biliary colic symptoms  
• Study drug compliance assessment  
• Comprehensive physical examination, vital signs, weight, assessment of Child- Pugh 
clinical features  
• 12-lead ECG  
• Questionnaires: S F-36, Chronic Liver Disease Questionnaire, AUDIT -C 
• Clinical laboratory evaluations ( after fasting at least 10 hours ): chemistry, hematology, 
coagulation, urinalysis, fibrosis markers, metabolic parameters (insulin, lipids, HbA1c), 
urine pregnancy test (for  females of reproductive potential)  
• Blood samples for biomarkers and population PK  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   53 of 90 
• Methacetin breath test (at select sites)  
• FibroS can® (at select sites)  
8.4.8  Follow -Up Phase ( 2 weeks after  Week 24 or Week 48)  
Subjects will be seen approximately 2  weeks after Week 24 or Week 48 (either at Week 26 or 
Week  50) or early termination.  Follow -up procedures will  consist of the following:  
• Review concomitant medications and other therapies (vitamins and dietary supplements)  
• Assessment for adverse events, including bili ary colic symptoms  
• Focused physical examination, v ital signs, weight , assessment of Child -Pugh clinical 
features  
• 12-lead ECG  
• Clinical laboratory evaluations : chemistry, hematology, coagulation, urinalysis, urine 
pregnancy test (for females of reproductive potential)  
• Blood sample for biomarkers  
8.5 PRIOR AND CONCOMITAN T MEDICATIONS  
Medications to treat complications of portal hypertension (e.g. non- selective beta blockers, 
nitrates, diuretics, lactulose, rifaximin, etc.) as well as statins should be maintained at a stable 
dose during the study if possible but may be adjusted if clinically indicated. Any changes to the 
dose or use  of these medications should be entered on the case report form.  Subjects should 
not take any potentially hepatotoxic drugs, herbal preparations, or supplements during the 
Screening period and throughout the study.    
Subjects should avoid taking new herbal preparations and supplements during the study that 
are chronically administered unless medically indicated. All prescription and ‘over -the-counter’ 
medications, including herbal preparations and supplements, taken by the subject at  Screening 
and through to study follow -up will be recorded on the Concomitant Medications case report 
form. The generic drug name, indication, dose, and dates of drug administration will be 
recorded. Any additions, deletions, or changes in the dose of these medications should be  
entered on the case report form. All subjects will be questioned about concomitant medication 
usage at each study visit.  No other investigational medication should be taken during the study 
except for methacetin as specified in the procedures for the methacetin breath test.  
8.6 OTHER PRECAUTIONS AND RESTRICTIONS DURING THE STUDY  
Subjects should be contacted prior to each study visit  to remind them to take their study drug 
the night before and the morning of the study visit  and to remind them to follow directi ons for 
fasting status for the relevant study visits . Subjects should be fasting (except for morning 
medications including study drug and NSBB which can be taken with water) at least 10 hours 
before study visits at Day 1,  Week 24, and Week  48.   
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   54 of 90 
8.7 SUBJECT AND STUDY TERMINATION  
8.7.1  Reasons and Procedures for Early Termination 
Subjects may be withdrawn from the study at their own request, upon request of the 
Investigator, or by the Sponsor at any time or for any reason.  Reasons for removing  a subject 
from the study may include:  
• subject withdrawal of consent;  
• Investigator decision (Investigator feels it is in the subject’s best interest to terminate participation)  
• the subject develops an AE necessitating withdrawal  
• subject non -compliance with study drug and/or study  procedures  
• subject lost to follow -up 
• major protocol violation  
• death  
• the study is terminated by the Sponsor  
• other reasons (e.g. subject requires an unacceptable concomitant medication, or pregnancy in a female study subject)  
 
If a subject is lost to follow -up (i.e., fails to return for study visits), reasonable efforts should be 
made to contact the subject and complete study termination procedures.  Efforts and means 
used to contact the subject should be recorded in the source documents.  
All subjects who di scontinue the study because of AEs  will be followed up at suitable intervals in 
order to evaluate the course of the AE and to ensure the reversibility or stabilization of the 
abnormality.  
All subjects who prematurely discontinue the study, regardless of the cause, should have an 
Early Termination visit scheduled as soon as possible after the discontinuation date.  For 
subjects who prematurely discontinue before Week  24, assessments scheduled at the Week  24 
visit should be performed, and f or subjects who prematurely discontinue after Week  24, 
assessments scheduled at the Week  48 visit should be performed (see Appendix I, Schedule of 
Events).  Study drug should be continued (unless the subject is discontinuing treatment due to 
an adverse event) until the Early T ermination visit is performed. A follow -up visit should then be 
scheduled to occur approximately 2  weeks following the Early Termination visit . 
8.7.2  Withdrawal from Study Drug Treatment but Not from Study Participation  
All efforts should be made to encourage subjects to continue participation in the study including 
undergoing all protocol -specified assessments even if they discontinue study drug treatmen t, 
unless they withdraw consent for participating in the study, are lost to follow -up, undergo liver 
transplantation, or the investigator deems that it is not in the best interest of the subject to 
continue participating in the study  or becomes unblinded to study drug assignment .  Subjects 
who meet criteria for withdrawal of study drug due to progression to Child- Pugh C or who 
develop a new or worsening  decompensation event should continue participation in the study, 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   55 of 90 
even if withdrawn from study drug.  Discontinuation of study drug should be documented in the 
database.  
8.7.3  Termination of the Study  
Participation in t he study by an Investigator may be terminated prematurely with sufficient notice 
in advance by the Investigator for any reason as per the terms of the contract with the Sponsor.  
The reason should be communicated in writing to the Sponsor.  
The Sponsor reserves the right to discontinue the study at any time for clinical or administrative 
reasons.  Such a termination must be implem ented by the Investigator, if instructed to do so by 
the Sponsor, in a time frame that is compatible with the subjects’ well -being.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   56 of 90 
9 INVESTIGATIONAL MEDIC INAL PRODUCT  
For the purpose of this protocol , the term ‘investigational medicinal product (IMP)’ is 
interchangeable with the term ‘study medication’ and/or ‘study drug’.  
All study medication (emricasan [IDN-6556]  and matching placebo) will be manufactured 
according to Good Manufacturing Practice (GMP).  
9.1 EMRICASAN AND PLACEBO SUPPLIES 
The double- blind suppli es of emricasan will be in bottles containing 60 capsules of emricasan 
(5, 25, or 50 mg).  Placebo will also be supplied in bottles containing 60 capsules. Each bottle 
will contain sufficient supply to dose subjects for four weeks.  
At the investigational s ite, emricasan and placebo supplies must be stored in a secure, lockable 
area. Excursions that are outside of the 15- 30 °C (59 to 86 °F) range will need to be reported.  
Subjects should be instructed to store their study drug bottles with the caps tightly closed in a 
safe area at room temperature (15-30 °C [59 to 86 °F] ).  Study drug bottles should not be stored 
near heating devices, at high temperatures or humidity, or where children or pets have access to them.  
9.2 INVESTIGATIONAL MEDIC INAL PRODUCT PACKAGI NG AND LABELING  
The packaging and labeling of study medication supplies will be performed according to GMP 
standards by a designated qualified vendor.  
Emricasan and placebo capsules will be dispensed to subjects in the provided bottles in 
sufficient quantities for continuation of treatment to at least the next scheduled visit, along with 
instructions for the proper method of taking the study drugs.   
All study drug bottles will carry  a uniquely numbered label that  will also contain the drug 
description and conditions for storage.   
9.3 INVESTIGATIONAL MEDI CINAL PRODUCT DISPENSING AND 
ACCOUNTABILITY  
All study drugs must be dispensed in the original containers provided by either the Sponsor or 
the drug manufacturer in order to assure stability of the drugs.  At each visit, subjects must be 
instructed to return all unused capsules in partially or completely full bottles in order to 
adequately assess each subject’s compliance with dosing instructions.  The number of capsules 
remaining in each  bottle should be counted at  each visit to assess subject compliance with 
study drug administration.  Also, except at the last dispensing visit, every bottle containing capsules should be re -dispensed to subjects, and subjects should be instructed to finish all 
capsules in each bottl e before opening a new bottle.  At the end of the study, all unused 
capsules and all dispensed bottles  (used , unused, or empty)  must  be returned by every subject 
for accounting.  
9.4 INVESTIGATIONAL MEDI CINAL PRODUCT ADMINI STRATION  
Subjects will be instructed to  take emricasan or placebo twice daily about the same time in the 
morning and evening without regard for food.  A ll study procedures specified at Day 1 should be 
performed prior to administration of the first dose of the investigational medicinal product.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   57 of 90 
10 WARNINGS AND PRECAUT IONS  
10.1 TERATOGENICITY AND FERTILITY  
Teratology studies conducted in rats and rabbits demonstrated that emricasan was 
teratogenic.   There have been no studies with this compound in pregnant women, but based on 
the preclinical findings, e mricasan has the potential to be teratogenic (refer to the Investigator’s 
Brochure  for further details).   Therefore, emricasan should not be used in pregnant women or 
women planning to become pregnant .   
Emricasan has also been found to reduce male and femal e fertility in rats.   There have been no 
studies on the effect of emricasan on fertility in men and women, but based on the preclinical 
findings, emricasan has the potential to reduce fertility in humans.  
10.2 CONTRACEPTION FOR FE MALE SUBJECTS OF REPRODUCTIVE 
POTENTIAL  
For the purposes of this study, females of reproductive potential are defined as any female who 
has experienced menarche and does not meet one of the following conditions:  
• Postmenopausal  
• Permanently sterile (i.e, . due to hysterectomy, bilateral salpingectomy or bilateral 
oophorectomy)  
o Tubal ligation is not  considered to be a permanent sterilization method  
 
A postmenopausal state  is defined as no menses for 12 months without an alternative medical 
cause.  A high follicle stimulating hormone [44]  level in the postmenopausal range may be used 
to confirm a post -meno pausal state in women not using hormonal contraception or hormone 
replacement therapy.  In the absence of 12 months of amenorrhea, a single FSH measurement 
in the post -menopausal range is not sufficient for a subject to be considered post -menopausal.  
Femal es of reproductive potential must undergo or adhere to the following procedures during 
the screening, treatment, and follow -up periods of the study to help ensure that they are not 
pregnant prior to starting treatment with study medication as well as to mi nimize exposure of the 
fetus to study medication should an unintentional pregnancy occur:  
• Serum pregnancy test at first screening visit (up to 6 weeks prior to Day 1)  
• Serum and urine pregnancy test at Day 1 
o Urine pregnancy test result should be confirmed negative before first dose of study 
drug is administered  
o A serum pregnancy test may detect a very early pregnancy approximately 1 week 
before a urine pregnancy test is positive. Subjects should be contacted as soon as 
possible if the serum pregnancy test is  positive.   
• Urine pregnancy test at all study visits after Day 1 
• Urine pregnancy test should be obtained in the event of a missed period by >7 days OR 
if unusual menstrual bleeding  occurs  
• Use effective contraception for at least 4 weeks prior to Day 1 and  continuing for at least 
4 weeks after the last dose of study drug 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   58 of 90 
Females of reproductive potential are strongly encouraged to use at least one of the following  
highly effective methods of contraception [45]: 
• Complete sexual abstinence during the entire duration of the study including the  follow -
up period  
• Intrauterine device or intrauterine hormone -releasing system , which has been shown to 
have a failure rate <1% within the first year of use under “typical use” conditions  
• Bilateral tubal ligation or occlusion 
• Partner who had vasectomy at least 3 months prior to Screening (only if the partner is 
the sole sexual part ner)  
 
If one of the above highly effective methods of contraception is not used, females of 
reproductive potential must  use 2 forms of contraception  (1 from each of the following 
2 categories):  
For subjects with compensated cirrhosis:  
1. combined (estrogen and progestogen containing) hormonal contraceptive (oral, transdermal, 
or vaginal) or  oral/injectable/implantable progestogen -only hormonal contraception AND  
2. barrier method such as a) male or female condom ( with or without spermicide) ; b) cap, 
diaphragm, or sponge with spermicide  
 
For subjects with decompensated cirrhosis:  
1. oral/injectable/implantable progestogen- only hormonal contraception AND  
2. barrier method such as a) male or female condom (with or without spermicide); b)  cap, 
diaphragm, or sponge with spermicide  
 
Note s: 
a) Combined oral contraceptives are considered medical eligibility criteria Category 4 (“A 
condition that represents an unacceptable health risk…”) in patients with 
decompensated cirrhosis [46] .  Combined oral contraceptives containing estrogens may 
therefore not be used in decompensated study subjects.  
b) Progestogen- only hormonal contraception, including levonorgestrel -releasing IUDs,  is 
considered to be Category 3 (“A condition for which the theoretical or proven risks 
usually outweigh the advantages…”) when used in patients with decompensated cirrhosis  [46].  If possible, a single highly effective method of contraception should be 
used in decompensated subjects.  However, the risk/benefit of progestogen contraception may be more favorable than usual in a decompensated subject  treated 
with emricasan who cannot or will not use a single highly effective method of 
contraception, since emricasan is  a potentially teratogenic drug.  
If pregnancy occurs in a female subject taking study drug, the subject should be instructed to 
immediately stop taking the study drug, and the Investigator should inform the Sponsor within 
24 hours of the Investigator’s learning of the pregnancy.  If the female subject is in the 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   59 of 90 
double- blind phase of the study, the treatment arm may be unblinded (after discussion between 
the Inves tigator and the Medical Monitor).  If pregnancy occurs  in a female subject after the 
double- blind phase of the study but within 4 weeks of taking study drug, the Investigator should 
inform the Sponsor immediately.  
If the female subject chooses to terminate the pregnancy, the Investigator should document the 
termination and contact the Medical Monitor to discuss whether continued participation of the 
subject in the study is appropriate.  If the female subject chooses to continue the pregnancy, the 
procedures  for withdrawing a subject from the study should be completed, and the Investigator 
should attempt to obtain information on the outcome of the pregnancy.  If the pregnancy goes to 
term, then the Investigator should also attempt to obtain information on the health of the infant 
after delivery and provide the information to the Sponsor.  
10.3 CONTRACEPTION FOR MA LE SUBJECTS WITH FEM ALE PARTNERS OF 
REPRODUCTIVE POTENTI AL 
All males , even those who are  permanently sterile through bilateral orchiectomy , should use a 
latex or synthetic condom during any sexual contact while on study drug treatment and for 
4 weeks after the last dose of study medication.  
If pregnancy occurs in the female partner of a male subject during the double- blind phase of the 
study or within 4 weeks of taking study drug, the Investigator should inform the Sponsor 
immediately.  The progress of the pregnancy in a male subject’s partner should be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination,  or spontaneous 
abortion).  If the pregnancy results in the birth of a child, additional follow -up information may be 
requested for the infant.  Follow -up will be performed to the extent permitted.  
10.4 USE OF E STROGENS IN SUBJECTS WITH D ECOMPENSATED CIRRHOSIS  
Estrogens have the potential to cause drug -induced liver injury (DILI) in patients with 
decompensated cirrhosis , and many estrogen product labels carry warnings or precautions for 
that patient population.  There are alternatives to estrogen -based contraceptives that are 
acceptable in decompensated cirrhosis; therefore estrogen- containing contraceptives should not 
be used for decompensated subjects in this study.  
Due to the risk of drug- induced liver injury, it is strongly recommended that estrogens not be 
used as hormone replacement therapy for subjects in this trial.  However, there may not be 
good alternatives to estrogens for the treatment of severe post-menopausal (estrogen -
withdrawal) symptoms.  If the Investigator and subject agree that the potential r isk of liver injury 
is outweighed by other benefits in that particular subject, estrogens may be cautiously used.  In 
that case, the lowest estrogen dose that results in adequate control of the most severe 
symptoms should be used.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   60 of 90 
11 DOCUMENTATION OF DAT A 
11.1 SOU RCE DOCUMENTATION 
Source data is all information in original records and certified copies of original records of 
clinical findings, observations and other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial. Source documents are any original document, data 
and records (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, 
subject diaries or evaluation checklists, pharmacy dispensing records, recorded data from 
automated instruments , any elec tronic medical record).  The clinical site study staff members 
will record the source data in their medical charts, except for data that are available on original 
printouts or as data files.   
All clinical work conducted under this protocol will be conduct ed according to GCP guidelines .  
This includes an inspection by the Sponsor and/or health authority representatives at any time.  The Investigator will agree to the inspection of study -related records by health authority 
representatives and/or the Sponsor.   If the study is to be audited by a health authority at a given 
site, the Investigator will agree to immediately notify the Sponsor upon receipt of the audit 
notification.  
11.2 DATA ENTRY IN DATABA SE 
All data will be entered electronically  by the study personnel using a validated Electronic Data 
Capture [47] database specifically designed for this study.  
11.3 QUERY CHECKS  
The raw data will be checked by appropriate programs for consistency and plausibility according 
to previously defined query checks documented in a data validation plan.  
11.4 CODING OF ADVERSE EV ENTS, DRUGS, AND DIS EASES  
After data entry, the AEs will be coded according to the MedDRA ( Medical Dictionary  for 
Regulatory Activities)  dictionary.  Concomitant medications will be coded according to the World 
Health Organization Drug Reference List.  
11.5 STUDY LANGUAGE AND  TRANSLATIONS  
The primary study materials (protocol, correspondence, clinical study report) will be prepared in 
English. However, where the first language of the subject, study personnel, or others involved in 
the study (such as Ethics Committees) is not English, appropriate arrangements will be made to 
have translations of the documents in the local language, as necessa ry.  In any case, a qualified 
translator will need to provide documentation to attest to the fact that the foreign language 
document is an accurate reflection of the respective English language document.  Any subject 
facing documents including the subject informed consent will also need to be translated and 
back translated by a qualified translator.  
Additional documents may need to be translated into English (e.g.,  transcripts of necessary 
additional hospital tests that may occur), and others (e.g.,  new safety information) may need to 
be translated into the local language.  The Sponsor, or designee, will make arrangements for 
such translations to occur promptly.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   61 of 90 
12 STATISTICAL M ETHODS  
12.1 INTRODUCTION 
Detailed methodology for summary and statistical analyses of the data collected in this study will 
be documented in a Statistical Analysis Plan (SAP), which will be dated and maintained by the 
Sponsor.  Should any of the assumptions of the statistical methods described below not be met, 
alternative methods will be applied and documented in the Clinical Study Report.  
12.2 PARAMETERS OF INTERE ST 
12.2.1  Safety Variables  
The following variables will be recorded for the safety evaluation:  
• Adverse events  
• Vital signs , weight , physical examination 
• Laboratory tests ( e.g. chemistry, hemat ology, coagulation, urinalysis)  
• ECGs  
• Liver and gallbladder events  and ultrasound  
 
12.2.2  Efficacy Variables  
The following variables will be recorded for the efficacy evaluation:  
Primary  
• HVPG  mean change from baseline at Week 24 
Secondary  
• HVPG response (based on 20% reduction from baseline)  at Week 24 
• Caspase 3/7 and ALT at Weeks 24 and 48  
Exploratory  
• HVPG response ( based on 10% reduct ion from baseline)  at Week 24 
• MELD and Child- Pugh scores , regression, and progression at Weeks 24 and 48 
• cCK18/M30, flCK18/M65, AST, total bilirubin, INR, and albumin at Weeks 24 and 48  
• Fibrosis markers  at Weeks 24 and 48  
• Health -related quality of life, as measured by SF- 36 and CLDQ , at Weeks 24 and 48  
• Clinical outcomes (development of decompensation or worsening of decompensation)  at 
Weeks 24 and 48  
• Liver metabolic functi on assessed by methacetin breath test (at select sites)  at 
Weeks  24 and 48  
• Liver stiffness by transient elastography (at select sites) at Weeks 24 and 48 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   62 of 90 
12.3 ANALYSIS POPULATIONS  
The Enrolled population will consist of all subject s who signed an informed consent form.  
The Full Analysis Set (FAS ) consists of all randomized subjects who have received at least 
one dose of study drug.  The analyses based on the FAS will be conducted on an 
intention- to-treat principle (i.e., all subjects will be analyzed with the group to which they were 
randomly assigned).   
The Per Protocol  Set (PPS) consists of all subjects in the FAS who do not have any significant 
protocol deviations.  
The Safety Analysis Set  consists of all subjects randomized and have received at least 
one dose of study drug on an “as treated” basis (i.e., all subjects will be analyzed by the 
treatment they have taken ).   
All efficacy analyses will be based on the FAS , with the primary analys is also being conducted 
using  the PPS.  All safety analyses will be based on the Safety Analysis Set.  
12.4 SAMPLE SIZE 
It is planned to enroll subjects into this study in order to randomize 240 subjects (60 subjects 
per group) to receive 1 of 3 treatment group s of emricasan or placebo.  Subjects will be 
randomly assigned to received either emricasan 50 mg BID, e mricasan 25 mg BID, emricasan 
5 mg BID, or matching placebo in a 1:1:1:1 ratio. Assuming a 20% attrition rate, it is expected 
that approximately 192 subjects (48 subjects per group) will have a Week 24 HVPG 
assessment.  
This sample size will provide 81% power to detect a statistically significant difference between 
at least 1 emricasan treatment group and placebo in the mean change from baseline in HVPG. 
This calculation assumes a mean difference between an active t reatment group and placebo of 
3 mmHg and a sample standard deviation of 4.5 mm Hg.  This calculation also applied a 
Dunnett’s adjustment of comparing 3 active treatment groups with placebo.  
The assumptions for the shape of the dose response was based on modelling of cCK18/M30 
data in HCV patients where the estimated ED50 was 1 mg total daily dose.  Based on data in the literature and discussion with key experts in the field, a clinically meaningf ul difference in the 
change from baseline in HVPG is approximately 2.5 - 3 mmHg, depending on the baseline 
value.  Subjects in Study IDN -6556 -11 (open- label pilot study evaluating the effect of emricasan 
on HVPG fo r 28 days) with a baseline HVPG  ≥12mmHg had a sample standard deviation of 
4.05 mmHg.  
12.5 STATISTICAL ANALYSES  
12.5.1  General  
All parameters will be analyzed using descriptive methods. Continuous parameters will be 
summarized using standard summary statistics as appropriate (n, mean, standard deviation, 
medi an, minimum, maximum).  Summary statistics for categorical variables will include number 
of observations  and percentages.   
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   63 of 90 
Analyses will be done using the validated statistical software of SAS® (version 9.3  or later).  
12.5.2  Safety Analysis  
Safety will be assessed by treatment compliance, treatment exposure, adverse events, 
gallbladder monitoring, potential DILI, laboratory tests, vital signs, physical examinations, ECGs, 
and prior/concomitant medications . All safety assessments will be summa rized descriptively.   
AEs will be tabulated by system organ class and preferred term. Summary of AEs by severity 
and relationship to treatment will also be provided.  
Change from baseline in laboratory parameters and vital signs will also be summarized 
desc riptively. Abnormal laboratory and ECG findings will be tabulated against appropriate cut -off 
points using frequency counts and percentages.  Any prior and concomitant medications will be 
described.  
12.5.3  Efficacy Analysis 
Primary Endpoint:  Mean Change from Baseline at Week 24 in HVPG  
The primary endpoint for this study is the change from baseline (CFB) at Week 24 in HVPG.  
The change from baseline will be calculated as HVPG at Week 24 minus HVPG at baseline 
(HVPGW24 -HVPGBL). Hence, a negative value will represent a decrease in HVPG at Week 24.  
Absolute and CFB values for the primary endpoint will be summarized descriptively by treatment group. Comparisons of the mean CFB in HVPG at Week 24 between each emricasan treatment 
group and placebo will be analyzed using  a fixed effects Analysis of Covariance (ANCOVA) 
model using the FAS.  This model will include the treatment group, compensated vs. 
decompensated status, and NSBB use as fixed effects with baseline HVPG as a covariate. 
Least -square adjusted means (LSMeans ) for each treatment group will be reported , along with 
the estimated difference in LSMeans  and corresponding 95% confidence intervals ( CIs).  A 
Dunnett’s test will be applied to adjust for the multiple comparisons of each emricasan treatment group with placebo.  
Missing data for the primary endpoint will be imputed using a multiple imputation technique as 
described in Section 14 of the SAP. Sensitivity analyses of the primary endpoint will be 
conducted using the following:  
• Repeat the primary analysis using observed cases  
• Repeat the primary analysis using the PP S 
• Tipping point analysis assessing impact of missing data  
Secondary Endpoints  
All secondary analyses will be conducted using the FAS.  No multiplicity adjustment s will be 
applied within or  across analyses  of secondary endpoints . 
The dose response of emricasan on portal pressure as assess by HVPG will be characterized 
using a plot of the CFB at Week 24 in HVPG across treatment group.  Treatment groups will be 
ordered as placebo, emricasan 5 mg BID, emricasan 25 mg BID, and emricasan 50 mg BID.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   64 of 90 
Absolute and CFB at each visit in Caspase 3/7 and ALT will be summarized descriptively by 
treatment group and visit.  Treatment comparisons for CFB at Week s 24 and 48 in Caspase 3/7 
and ALT will be conducted us ing a similar ANCOVA model as described for the primary 
analysis, using the appropriate baseline value.  
If the CFB at each visit in caspase 3/7 and ALT is  deemed to be transformed, the geometric 
mean will also be provided.  In this scenario, t he relative c hange from baseline at Week s 24 and 
48 will be calculated for caspase 3/7 and ALT by back transforming the change from baseline in 
log-transformed data.  
Exploratory Endpoints 
All exploratory endpoints will be summarized descriptively by treatment group and visit.  
Treatment comparisons for continuous endpoints will be conducted at Weeks 24 and 48  in a 
similar ANCOVA model as the primary analysis, using the appropriate baseline value. Treatment comparisons for response, regression, and progression endpoints will be analyzed 
using a logistic regression model using treatment group, compensated vs. decompensated 
status, and NSBB use as fixed effects and the appropriate baseline value as a covariate . 
Adjusted odds  and risk  ratios for each comparison of emricasan with placebo will be provided 
along with the corresponding 95% CI.  
Safety Endpoints 
All safety endpoints will be summarized descriptively by treatment group.  
12.5.4  Timing of Analyses  
After the last subject completes their  Week 24 visit, all data for all subjects across all visits will 
be cl eaned, locked, and considered as the main analysis for this study.  This Week 24 analysis 
will include all primary, secondary, and exploratory endpoint analyses.  Although the Sponsor will be unblinded for  the Week 24 analysis, the investigative sites will remain blinded throughout 
the study.  The purpose of the Week 24 analysis is internal decision making.  
The final analysis of the study (i.e., Week 48 analysis) will be conducted after all subjects have 
completed all study visits up to and including the follow -up visit.  All study data across all 
subjects and visits will be cleaned and locked for this final analysis.  
12.6 HANDLING OF MISSING DATA  
Missing data for the primary endpoint will be imputed using a multiple imputation analysis, 
assuming t hat the missing data pattern is missing at random. The pattern and amount of 
missing data pattern will be assessed to determine the number of imputed datasets to be 
derived for the multiple imputation analysis.  The SAS multiple imputation procedure will be 
used to generate multiply imputed datasets (roughly the percent attrition seen in the study), with each multiply imputed dataset being analyzed as described for the primary endpoint analysis.   
The r esults for each imputed dataset analysis will then be summarized using the SAS 
MIANALYZE procedure with the appropriate statistics to be reported.  
Imputed values will be dependent on examination of treatment group and potential risk factors, 
such as age, gender, compensated/decompensated status, use of NSBB, baseline MELD 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   65 of 90 
score, and baseline C -P classification.  A monotone regression method will be applied to impute 
missing CFB at Week 24 HVPG values.  
An LOCF method will also be applied to the primary endpoint in the cases where an HVPG 
measurement is provided prior to Week 24.  
No imputation methods will be applied for secondary or exploratory efficacy and all safety 
endpoints.  
12.7 DATA MONITORING COMM ITTEE (DMC)  
An independent DMC will review unblinded safety  data from this study approximately every 
three months .  Members of the DMC will not be allowed to participate as Investigators in this 
study and will not otherwise consult for the Sponsor.   
A charter, which will include a detailed description of the scope and the extent of its 
responsibilities and procedures, will be implemented prior to any data review.  These 
documents (charter, open and closed meeting minutes, etc.) will be considered part  of the study 
documentation, but not of this protocol.  The DMC will review data within its general remit to 
oversee subject safety in the study, and provide recommendations and guidance to the Sponsor 
in accordance with the procedures stated in its charte r.  
All Investigators, responsible IRB/IECs, and applicable regulatory agencies will be informed of 
any decisions made by the Sponsor based on recommendations from the DMC r elating to 
subject safety that  affect the conduct of this study.  The Investigators  will inform the subjects of 
such actions , and the protocol and ICF will be revised, as appropriate.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   66 of 90 
13 SAFETY MONITORING AN D REPORTING  
13.1 ADVERSE EVENT REPORTING OBLIGATION S 
The Investigator is responsible for recording adverse events observed during the study.   In 
addition, certain adverse events (as described in Section 13.2 below ) are classified as “serious” 
and must be reported within 24 hours to Conatus or its designee.  
In the case of certain adverse events, the Investigator and the Medical Monitor, after discussing 
the details of the adverse events, may decide to temporarily interrupt dosing or permanently 
discontinue study drug treatment in a subset  of subjects or in entirety.  
13.2 ADVERSE EVENT DEFINI TIONS  
The following definitions of terms are guided by the ICH and 21 CFR 312.32 and are included 
herein.  
An adverse event is any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered study drug related.  
Adverse events include, but are not limited to:  
• Any symptom or condition not previously reported by the subject (medical history).  
• An exacerbation of a pre -existing symptom or condition.  
• A significant increase in frequency or intensity of a pre -existing episodic event or 
condition.  
• A drug interaction.  
• A condition first detected or diagnosed after study drug administration even though it may have been present prior to the start of the study.  
 
An AE does not include:  
• Medical or surgical procedures (e.g., surgery, endoscopy, tooth extraction, or blood 
transfusion); the condition that leads to the procedure is an adverse event (e.g., bleeding 
esophageal varices, dental caries).  
• Overdose of either study drug or concurrent medication without any clinical signs or 
symptoms.  
 
Suspected adverse reaction means any adverse event for which there is a reasonable 
possibility that the drug caused the adverse event.  For the purposes of safety reporting, 
‘reasonable possibi lity’ means there is evidence to suggest a causal relationship between the 
drug and the adverse event.  A suspected adverse reaction implies a lesser degree of certainty 
about causality than adverse reaction, which means any adverse event caused by a drug.  
An adverse reaction is any adverse event caused by  a drug.  Adverse reactions are a subset of 
all suspected adverse reactions for which there is reason to conclude that the drug caused the event.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   67 of 90 
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either 
the Investigator or Sponsor, it results in any of the following outcomes:  
• Death 
• A life -threatening adverse event  
• Inpatient hospitalization or prolongation of existing hospitalization 
• A persistent or significan t incapacity or substantial disruption of the ability to conduct 
normal life functions  
• A congenital anomaly/birth defect  
 
Important medical events that may not result in death, be life- threatening, or require 
hospitalization may be considered serious when,  based upon appropriate medical judgment, 
they may jeopardize the subject and may require medical or surgical intervention to prevent one 
of the outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring int ensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.  
Hospitalizations that fulfill the serious criterion are generally greate r than 24 hours in duration. 
The Investigator should use appropriate medical judgment to determine if a hospitalization less than 24 hours in duration should be considered serious.  
A prescheduled or elective procedure or a routinely scheduled treatment wil l not be considered 
serious, even if the subject is hospitalized,  as long as the study site documents all of the 
following:  
• The condition that required the prescheduled or elective procedure or routinely 
scheduled treatment was present before and did not w orsen or progress in the opinion of 
the Investigator between the subject’s consent to participate in the study and the scheduled procedure or treatment  
• The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the inter vention or hospital admission 
 
An adverse event or suspected adverse reaction is considered “life- threatening” if, in the view of 
either the Investigator or Sponsor, its occurrence places the subject at immediate risk of death. It does not include an adver se event or suspected adverse reaction that, had it occurred in a 
more severe form, might have caused death.  
An adverse event or suspected adverse reaction is considered ‘unexpected’ if it is not listed in the Investigator B rochure (or reference safety inf ormation)  or is not listed at the specificity or 
severity that has been observed.  
The adverse events and their time- adjusted incidence rates in  Table 4 are consi dered 
anticipated events in patients with cirrhosis and portal hypertension (the study protocol 
population)  and will not be individually reported in an expedited fashion by the Spons or. The 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   68 of 90 
Investigator is still obligated to report all SAEs whether considered anticipated or not. The 
severity of these events may be up to severe.  
Table 4. Time -Adjusted Incidence Rate for Anticipated E vents in Patient Population  
Preferred Term  Time Adjusted 
Incidence Rate  
(per patient- year)  Preferred Term  Time Adjusted 
Incidence Rate  
(per patient- year)  
Ascites  0.121  Lobar pneumonia  0.016  
Hepatic encephalopathy  0.121  Pleural effusion 0.016  
Hepatic failure  0.067  Bacteremia  0.012  
Cellulitis  0.052  Biliary cirrhosis primary  0.012  
Hepatic cirrhosis  0.052  Dehydration  0.012  
Renal failure acute  0.052  Dyspnea  0.012  
Hyperkalemia  0.032  Gastroenteritis  0.012  
Hyponatremia 0.032  Hydrothorax  0.012  
Pneumonia  0.032  Mental impairment  0.012  
Urinary tract infection  0.032  Respiratory failure  0.012  
Hepatorenal syndrome 0.030  Septic shock  0.012  
Oesophageal varices 
haemorrhage  0.030  Dizziness  0.008  
Hepatic neoplasm malignant  0.028  Hypoglycemia 0.008  
Peritonitis bacterial  0.028  Liver transplant rejection  0.008  
Clostridium colitis  0.020  Metabolic encephalopathy  0.008  
Hyperglycemia 0.020  Syncope  0.008  
Renal failure  0.020  Hypotension  0.004  
 
There are no anticipated AEs with methacetin.  
The Sponsor will determine if a SUSAR or  SAE meets the criteria of being reportable as a 7- day 
or a 15- day safety report.  
13.2.1  Pre-Treatment -Emergent Adverse Events  
The Sponsor considers adverse events that occur between the time  that the subject signs the 
informed consent form for the study and the time when that subject is first administered the 
study drugs as “pre -treatment -emergent” events. The start date (and time if necessary) of any 
adverse events that occur between signing of t he informed consent form and the first dose of 
study drug should be recorded to allow correct classification of these adverse events as 
pre-treatment -emergent.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   69 of 90 
13.2.2  Laboratory Abnormalities as Adverse Events  
Many laboratory abnormalities observed during the course of a study will be included under a 
reported adverse event describing a clinical syndrome ( e.g., elevated blood urine nitrogen 
[BUN]  and creatinine in the setting of an adverse event of renal failure, or decreased 
hemoglobin in a case of bleeding esophageal varices).  In such cases, the laboratory 
abnormality itself ( e.g., elevated creatinine in a setting of renal failure) should not be recorded 
as an adverse event.  However, isolated laboratory abnormalities should be reported as adverse 
events if they  are considered adverse by the Investigator.  Criteria for an adverse laboratory 
abnormality  in this study include:  
1. A laboratory abnormality that leads to a dose- limiting toxicity ( e.g., an abnormality that 
results in study drug dose reduction, suspension or discontinuation), or  
2. A laboratory abnormality that results in any therapeutic intervention ( i.e., concomitant 
medication or therapy), or  
3. Other laboratory abnormality judged by the Inv estigator to be of any particular clinical 
concern ( e.g., significant fall in hemoglobin not requiring transfusion).  
13.3 SEVERITY OF ADVERSE EVENTS  
The Investigator must categorize the severity of each adverse event according to the following 
guidelines:  
Mild:  Associated with no limitation of usual activities or only slight discomfort; generally 
not requiring alteration or cessation of study drug administration; and/or not 
needing therapeutic intervention.  
Moderate:  Associated with limitation of usual activiti es or significant discomfort; generally 
requiring alteration or cessation of study drug administration; and/or requiring therapeutic intervention.  
Severe:  Associated with inability of subject to carry out usual activities or very marked 
discomfort; consid ered to be life- threatening; resulting in significant disability or 
incapacity; and requiring therapeutic intervention.  
13.4 CLASSIFICATION OF AD VERSE EVENTS BY RELA TIONSHIP TO STUDY 
DRUG ADMINISTRATION 
The Investigator must determine whether each adverse event  is related to study drug  
(emricasan or placebo) and whether each adverse event  is related to methacetin 
(investigational  drug for the methacetin breath test) .  The relationship of each adverse event will 
be assessed by the Investigator after careful consi deration, and according to the following 
guidelines:  
Definitely:  A reaction that follows a reasonable temporal sequence from administration of 
study drug; that follows a known or expected response pattern to the study drug; 
it disappears or decreases on ce ssation or reduction in study drug dose; and/or it 
reappears or worsens when the study drug is administered.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   70 of 90 
Probably:  A reaction that follows a reasonable temporal sequence from administration of 
study drug; that follows a known or expected response pattern to the study drug; 
and/or that could not be reasonably explained by other factors such as 
underlying disease, complications, concomitant drugs, or concurrent treatments.  
Possibly:  A reaction that follows a reasonable temporal sequence from administration of 
study drug; that follows a known or expected response pattern to the study drug, 
but that could reasonably have been produced by a number of other factors 
including underlying disease, complications, concomitant drugs, or concurrent 
treatments.  
Unlike ly: A reaction that does not follow a reasonable temporal sequence from 
administration, and/or that can be reasonably explained by other factors, 
including underlying disease, complications, concomitant drugs, or concurrent 
treatments.  
Not Related:  A react ion for which sufficient data exist to indicate that the etiology is unrelated 
to the study drug.  
For the purposes of regulatory reporting, AEs assessed as definitely, probably, and possibly 
related are considered related to study drug.  
13.5 RECORDING AND REPORTING ADVERSE EV ENTS  
13.5.1  Recording Adverse Events  
All adverse events will be recorded in the appropriate section of the case report form. AEs 
(except SAEs, see Section 13.8) should be collected for a subject starting from signing of the 
informed consent until the subject’s last study visit (follow -up visit, early termination, or last 
regularly scheduled study visit).  Subjects withdrawn from the study due to adverse events will 
be followed by the Investigator until the outcome is determined and, when appropriate, 
additional written reports and documentation will be provided.  The Investigator should always 
group signs and symptoms into a single term that constitutes a single uni fying diagnosis if 
possible.  
If the adverse event meets the definition of a serious adverse event, or if the Investigator becomes aware of an unexpected adverse event that places the subject at risk or a pregnancy 
at any time after the study drug administration up to the end of the study follow -up period, the 
event must be documented and reported as described in Section 13.5.2 . 
13.5.2  Investigator Reporting of a Serious Adverse Event  
In agreeing to the provisions of this protocol, the Investigator accepts all legal responsibilities for prompt notification of serious adverse events to the Sponsor or designee in the EDC of the 
study and at the contact listed below .  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   71 of 90 
Contact  
SynteractHCR Safety  
Safety Fax:  +1-760-268-6500  
safetyfax@synteracthcr.com  OR 
if not available  Mason Yamashita, MD  
VP, Pharmacovigilance 
Office:  +1-858 376 2617  
Mobile:  +1-619 306 2125  
myamashita@conatuspharma.com  
 
All serious adverse events must  be reported to the Sponsor or designee within 24 hours after 
the Investigator recognizes/classifies the event as a serious adverse event. The following 
information should be provided at the time of the initial report:   subject number, a description of 
the event, the Investigator judgment of study drug causality, at least one criterion classifying the 
event as serious, and the name and title of the reporting individual.    
After the initial report, as necessary, the Investigator will provide follow -up inform ation on a 
serious adverse event to the Sponsor or designee within 24 hours after he/she receives that information. Examples of follow -up information include hospital records, case reports, autopsy 
reports, and other pertinent documents.  
The Sponsor will c onsider the Investigator’s assessment of the causality; however, since the 
Sponsor will assess the overall safety of the study medication, the Sponsor’s causality 
assessment will take precedence, unless the Investigator’s assessment must take precedence 
per country -specific regulations.  
13.6 ADDITIONAL INVESTIGA TOR RESPONSIBILITIES  ON FOLLOW -UP OF 
SERIOUS ADVERSE EVEN TS 
The Investigator and supporting personnel responsible for subject care should discuss with the 
Medical Monitor any need for supplemental invest igations of serious adverse events. The 
results of these additional assessments conducted must be reported to the Sponsor. If a subject dies during participation in the study and a post -mortem examination is performed, a copy of the 
autopsy report must be submitted to the Sponsor.  
13.7 FOLLOW -UP OF ADVERSE  EVENTS  
All SAEs must be followed until the event resolves, the condition stabilizes, the event is 
otherwise explained, or the subject is lost to follow -up.  The Investigator is responsible to ensure 
that follow -up includes any supplemental investigations as may be indicated to elucidate the 
nature and/or causality of the adverse event.  This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health care 
professionals as is practical.  
All non -serious adverse events must be followed until the final study visit, at which point the 
status of the event (e.g. ongoing, stabilized, resolved) should be documented on the case report form, with date of resolution if the event is resolved.   
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   72 of 90 
13.8 NOTIFICATION OF POST -STUDY SERIOUS ADVER SE EVENTS  
Investigators are not obligated to actively follow subjects after the completion of the study. 
However, if the Investigator becomes aware of a serious adverse event, he/she should notify 
the Sponsor if such an event is attributable to study drug. The notification to the Sponsor of a post-study serious adverse event by the Investigator should occur within 24 hours of becoming 
aware of the serious adverse event.  
13.9 IRB/IEC NOTIFICATION OF SERIOUS AD VERSE EVENTS  
The Investigator is responsible for promptly notifying her/his IRB/IEC of all serious adverse 
events, including any follow -up information, occurring at her/his site. In addition, the Investigator 
is responsible for submitti ng information on SUSARs/SAEs received from the Sponsor to her/his 
local IRB/IEC.   However, in some countries, the notification of SUSARs/SAEs to the IRB/IEC 
will be the responsibility of the Sponsor or Sponsor’s designee.  Documentation of the 
submissions  to IRB/IEC must be retained in the appropriate study file(s).  
13.10  HEALTH AUTHORITY SAF ETY REPORTS  
The Sponsor or its representatives will submit a safety report to the US Food and Drug 
Administration (FDA) and any other appropriate regulatory agencies in accordance with country 
specific requirements, for any serious adverse event that is unexpected and related to the study 
drug within the appropriate time frame.  The Sponsor or its representatives will send copies of 
each safety report submitted to the FDA and  other regulatory agencies to the Investigators who 
are actively participating in Sponsor clinical studies.  Safety reports must be submitted to the 
appropriate IRB/IEC as soon as possible.  Documentation of the submission to the IRB/IEC 
must be retained f or each safety report.  As instructed by the Sponsor or its designee, safety 
reports should be retained in the appropriate study files  or with the Investigator’s Brochure .  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   73 of 90 
14 ADMINISTRATIVE ASPEC TS 
14.1 INVESTIGATOR RESPONSIBILITIES FOR GENERA L STUDY CONDUCT  
It is the Investigator’s responsibility to ensure that:  
• The protoc ol, subject information sheet, proposed informed consent form, trial 
participation card (if applicable), or any information to the Primary Care Physician and 
any advertisement for subject recrui tment  are reviewed and approved by the appropriate 
IRB/IEC, prior to the start of the study.  
• The proposed subject information sheet, informed consent form, trial participation card (if 
applicable) and any proposed advertisement are agreed to by the Sponsor . 
• A copy of the IRB/IEC approval letter  for the protocol, any amendments, the subject 
information sheet, the informed consent form, the trial participation card (if applicable) 
and any advertisements  are supplied to the Sponsor prior to starting the study.   
• During the course of the study, at intervals not exceeding one year, timely and accurate 
reports are submitted to the IRB/IEC on the progress of the study and any other local IRB/IEC regulations regarding reporting are satisfied.  
• Copies of all reports to and correspondence with and from the IRB/IEC  are provided to 
the Sponsor.  
• At the completion or early termination of the study, a final report is made to the IRB/IEC 
within the applicable IRB/IEC time frames.  
• Any significant deviation in the study protocol  or any change that may alter subject risk is 
approved by the Sponsor (and FDA/other regulatory agency review and/or approval is 
obtained if required) and is approved in writing by the IRB/IEC prior to implementation.  
All protocol amendments will be submi tted to the IRB/IEC.   
• Receipt of administrative amendments provided for information only  are acknowledged.   
• An approval/favorable opinion is obtained from the IRB/IEC on substantial amendments 
prior to implementation, unless the amendment is necessary to reduce immediate risk to 
study participants.  
• A written notice of approval from the Sponsor is obtained prior to initiating changes to 
the study protocol.  
14.2 PROTOCOL DEVIATIONS  
Unless there is a safety concern, there should be no deviations or violations of the study protocol.  In the event of a safety concern, the Investigator or designee must document and 
explain the reason for any deviation from the approved protocol.  The Investigator may 
implement a deviation from, or a change to, the protocol to elimina te an immediate hazard to 
study participants without prior IRB/IEC approval.  Immediately after the implemented deviation 
or change, the Investigator must submit a report explaining the reasons for the protocol violation 
or deviation to the IRB/IEC, Conatus, and to the regulatory authorities, if required.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   74 of 90 
14.3 SUBJECT INFORMATION AND CONSENT  
Prior to participation in any study -specific procedures, the subject must sign an IRB/IEC -
approved written Informed Consent Form in his/her native language (note: all refere nces to 
“subject” in this section refers to the study subject or his/her legally acceptable representative) .  
The approved written informed consent must adhere to all applicable laws in regards to the 
safety and confidentiality of the subjects.  To obtain and document informed consent, the 
Investigator should com ply with applicable regulations  and adhere to ICH GCP standards and 
the ethical principles in the Declaration of Helsinki (October 2008).  
The language in the written information about the study should be as non -technical as practical 
and should be understandable to the subject.  Before informed consent is obtained, the 
Investigator should provide the subject ample time and opportunity to inquire about the study 
and to decide whether or not to partici pate.  
All questions about the study should be answered to the satisfaction of the subject.  The written 
Informed Consent Form should be signed and personally dated by the subject and the person 
who conducted the informed consent discussion, with any additional s ignatures obtained as 
required by applicable local regulations and IRB/IEC requirements.  Each subject will be informed that participation is voluntary and that he/she can withdraw from the study at any time.  
All subjects will receive a copy of the signed  and dated Informed Consent Form.  
14.4 SUBJECT CONFIDENTIAL ITY AND DATA PROTECT ION 
The processing of personal data in pursuit of this study will be limited to those data that are 
reasonably necessary to investigate the utility of the study medications used in this study.  
These data will be processed with adequate precautions to ensure confidentiality according to 
local laws.   
The Sponsor  ensures that the personal data are:  
• collected for a specified and legitimate purpose  
• processed fairly and lawfully  
• accurate  and up to date  
 
Explicit consent for the processing of personal data will be obtained prospectively from the 
participating subject.   The Sponsor  and/or designees whose responsibilities require access to 
personal data agree to keep the identity of study subjects confidential.  This confidentiality will be maintained throughout the complete data processing.   Study subjects will be entitled to 
request confirmation of the existence of personal data held by the Sponsor  and will have the 
right to rectify erroneous or inaccurate data prior to database lock.  
14.5 LABORATORY ACCREDITA TION  
Any laboratory facility intended to be used for analysis of clinical laboratory samples required by 
this protocol must provide evidence of adequate licensure or accreditation according to the 
prevailing regulations in that state and/or country. Reference values and/or normal ranges for 
the test results must be provided to the Sponsor.  The Sponsor must be notified promptly in 
writing of any reference value changes during the course of the study.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   75 of 90 
This protocol will analyz e pharmacokinetics of emricasan and exploratory serum biomarkers of 
caspase activity.  As such, some of the analytes may be tested at a non -accredited research or 
analytical laboratory.  The requirement for adequate licens ure or accreditation will not apply to 
any research or analytical laboratories utilized in this protocol.  
14.6 REQUIRED DOCUMENTS  
The Investigator and affiliated institution shall maintain the study documents and records as 
specified in “ Essential Documents for  the Conduct of a Clinical Trial” (ICH E6 Section 8), and as 
required by the applicable regulatory requirement(s).  This includes, but is not limited to the 
protocol, Case Report Forms ( CRF)s, AE reports, subject source data (original records or 
certified copies), correspondence with health authorities and IRB/IEC, consent forms, 
Investigator’s curriculum vitae, monitor visit logs, laboratory reference ranges and laboratory 
certification or quality control procedures and laboratory director curriculum vitae.  Subject 
source data must be maintained as original records or copies certified after verification as being accurate and complete.  The Investigator and affiliated institution should take measures to 
prevent accidental or premature destruction of documents. 
14.7 STUDY MONITORING  
The Sponsor  or designee will monitor this clinical study through study site visits scheduled to 
check the adequacy of site staff and facilities  and to ensure adherence to the protocol, study 
procedures , and applicable regulations.  The  site monitor will also assess proper CRF 
completion and source document retention.  The Investigator and study site staff are expected 
to provide adequate space for monitoring visits and to allocate sufficient time to permit adequate 
review of the study’s  progress.  The Investigator will permit study -related monitoring, audits, 
IRB/IEC review and regulatory inspection(s), providing direct access to source data/documents 
including electronic medical records and study related facilities (e .g., pharmacy, diag nostic 
laboratories).  
14.8 ELECTRONIC DATA RECO RD AND CASE REPORT F ORMS  
Where referenced in this protocol, CRFs refer to electronic CRFs, as defined for the study.  A 
CRF must be completed for each subject who has given informed consent.  In the case of 
screeni ng failure, the following data will be entered into the CRF at a minimum : visit date, 
demography and reason for screen failure.  All entries into the CRF are ultimately the responsibility of the Investigator before adding his/her signature.  
The CRF must be completed at the time of, or shortly after the subject's visit, with the exception 
of results of tests performed outside the Investigator's office, so that they always reflect the 
latest observations of the subjects participating in the study.  If certain information is Not Done, 
Not Available or Not Applicable, the Investigator must record this according to the CRF 
completion instructions.  
The CRF and source documents must be made available to the site monitor.  During monitoring 
visits, the site monitor will review the CRF entries and evaluate them for completeness and 
consistency.  The CRF entries will also be compared with the source documents to ensure that there are no discrepancies for critical data.  All entries, corrections , and alterations are to be 
made by the responsible Investigator or his/her designee.  The site monitor may query the data, 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   76 of 90 
but cannot edit CRF entries recorded by the site designee.   A copy of each subject ’s CRF will be 
maintained by the Investigator.  
14.9 DRUG ACCOUNTABILITY  
The inv estigational drug is to be prescribed only by the Principal Investigator or physician sub-
Investigators named on the Form FDA 1572 or foreign equivalent.  Under no circumstances will 
the Investigator(s) allow the investigational drug to be used other than as directed by this 
protocol.  
The Investigator must maintain accurate records accounting for the receipt of the investigational 
drug supplies and for the disposition of the drug.  Documentation of the disposition of the drug 
should consist of a dispensing record including the identification of the person to whom the drug 
is dispensed, the quantity and the date of dispensing, and any unused drug returned.  This record is in addition to any drug accountability information recorded on the case report forms.  
At the termination of the study or at the request of the Sponsor, the Investigator must return any 
unused study medications and all partially dispensed or empty containers to the Sponsor or its 
designee according to applicable local and country regulations.   If return of drugs  is not feasible, 
the Sponsor will supply instructions as to how the supplies may be destroyed.  Drug supply destruction must be clearly documented. Any investigational drug return will be documented at 
the Sponsor.  The Investigator wi ll also provide a written explanation for any missing study 
drugs.  
14.10  RECORD RETENTION 
Documents that individually and collectively permit evaluation of the conduct of the study and 
the quality of the data produced must be maintained for review by the Sponsor ’s Quality 
Assurance auditors and by US  and non- US regulatory authorities. The period of time these 
documents must be maintained is governed by US and non- US regulations.  International 
requirements specify that these documents are to be maintained for 15 years or longer after a 
drug is approved for marketing.  The Sponsor or its designee(s) will inform the Investigator 
when these documents may be destroyed.  The Sponsor or its designee(s) must be notified in 
writing at least  6 months  prior to the intended date of disposal of any study record related to this 
protocol to allow the Sponsor to make alternate storage arrangements.  
If the Investigator relocates, retires, or for any reason withdraws from the study, the Sponsor 
should be prospectively notified.  The study records must be transferred to an acceptable 
designee, such as another Investigator, another institution, or to the Sponsor.  
14.11  FINANCIAL DISCLOSURE  
The Investigator’s disclosable financial interests must be obtained prior to initiation of the study site, at completion of the study at the investigational site, and 1 year following study completion.  
It is the investigator’s responsibility to promptly update this information if any relevant changes 
occur during the above described period.  Any disclosable financial interests will be recorded on 
the Investigator Financial Disclosure Form.  
Any Investigator(s) added as investigational staff to the form FDA  1572 must complete the 
Investigator Financial Disclosure Form at the beginning of his/her participation in the study.   
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   77 of 90 
14.12  INVESTIGATOR’S FINAL  REPORT  
Each Investigator will submit, shortly after completion of study participation, a final, written 
report to the Sponsor.  
14.13  PUBLICATION POLICY  
The Sponsor intends to publish the results of all of the clinical studies that it sponsors.  
Consistent with the recommendations of the editors of several leading medical journals, the 
International Committee of Medical Jour nal Editors (ICMJE),  authorship of publications resulting 
from Sponsor studies should fairly recognize the activities of those that have made a significant contribution to the study [48]. Thus, it is anticipated that authorship will reflect the contribution 
made by the Sponsor personnel, the Investigators , and others involved such as statisticians.  
In recent years, issues about conflicts of interest and accuracy of the study data have been 
raised in the medical press.  Accordingly, the Sponsor has developed publication guidelines for 
clinical studies that are appropriate for this study.  Key issues include:  
• Responsibilit y: Each Principal Investigator is responsible for the accuracy and 
completeness of all data from his/her site. The Sponsor (or its representatives) is (are) 
responsible for the accuracy of the data entered into the study databases and for the 
accuracy of t he analyses conducted.  
• Authorship and Publication Committee:  The Sponsor, in collaboration with the 
Investigators, will establish the appropriate authorship and responsibility for drafting 
study documents in accordance with the principles of the ICMJE. It is anticipated that a 
publication committee will be formed to assume oversight of these activities. All 
manuscripts will be reviewed and agreed upon by all authors before submission for 
publication.  
• Sponsor Review of External Manuscripts:  Consistent with the previous bullet point, 
drafts of any and all publications or presentations that may arise from this study must be 
subm itted to the Sponsor for review and approval  and to ensure consistency with the 
policy in this protocol.  The Sponsor will have the ri ght to request appropriate 
modification to correct facts and to represent its opinions, or the opinions of the 
publication committee, if these differ with the proposed publication.  Any Investigator 
who plans to submit  material for publication must adhere to the following procedure for 
Sponsor review and approval:  
a. The Investigator will notify the Sponsor of his/her intent to publish and/or present 
results of the study at least 30 days prior to submission for publication or the 
scheduled presentation date. T he notification should be made in writing to the Vice 
President, Clinical Development.  
b. The Investigator shall provide to the Sponsor the full details of the proposed publication or presentation in electronic format at minimum 14 (fourteen) days prior 
to submission for publication of any paper, lett er or similar publication, or 7
 (seven) 
days prior to submission for presentation of any abstract, poster, talk , or any other 
presentation.  
c. The Investigator shall give reasonable consideration to any request by the Sponsor 
to make changes within the periods mentioned in (b) above.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   78 of 90 
d. The Investigator shall remove confidential information requested by the Sponsor 
before finalizing the publication.  
e. Upon written request from the Sponsor, the Investigator agrees not to submit data for 
publication/presentation for an additional 60 (sixty) days in order to allow for actions 
to be taken which might be necessary to preserve rights for patent protection.  If 
such written request is not made within the periods mentioned in (b) above, the 
Sponsor will be deemed to have waived the right to delay.  
f. In any case, the Investigator will also provide a final version, in exactly the form that was submitted for publication, to the Sponsor simultaneously with that submission; 
this shall also  apply to any revised versions that are submitted following review by 
the journal (etc.) in which publication is projected.  
• Confidentiality:   Investigators will conduct all interactions with the Sponsor and with 
third parties consistent with the executed c onfidentiality agreements.  While publication, 
by intention, presents the critical scientific data in a public forum, some information (such 
as future plans, results of nonclinical studies, or chemical formulae) may still need to 
remain confidential.  
• Medical Journal Review:   Consistent with the intention of the Sponsor to publish the 
study in a fair and accurate manner, the Sponsor supports diligence in the publication 
review process of medical journals.  Accordingly, upon request, all pertinent study data 
and information will be made available as supplemental information for journal editors 
and reviewers to evaluate and audit, e.g., protocol and amendments, data tabulations, 
etc.  The journal and reviewers will need to make arrangements to maintain the 
confidentiality of such supplemental information, where relevant, and the Sponsor will 
make suitable arrangements to ensure that the identity of journal reviewers is kept 
confidenti al.  Records will be maintained of reviewers and the respective documents and 
datasets that were reviewed by each of them.  
• Internet Clinical Study Listing:  In addition, also consistent with the recommendations 
of the ICMJE, the Sponsor will make available appropriate information regarding the 
study via the internet. This will include registration and listing of the study on 
www.clinicaltrials.gov, the US National Institutes of Health listing of clinical studies.  
14.14  CONFIDENTIALITY  
The Sponsor, its designees, and all clinical site personnel affirm and uphold the principle of the 
subject’s right to protection against invasion of privacy.  Throughout this study, all data will be 
identified only by an identification number.  
All information concerning this study and the Sponsor’s development of emricasan that is not 
previously published is considered confidential information.  This confidential information shall remain the sole property of the Sponsor.  It shall not be disclosed to others without written 
consent of t he Sponsor and shall not be used except in the performance of this study.  
The information compiled during the conduct of this clinical study is also considered confidential 
and may be disclosed and/or used only by the Sponsor as they deem necessary. To all ow the 
use of the information derived from this clinical study and to ensure compliance to current federal and international regulations, the Investigator is obliged to furnish the Sponsor with 
complete test results and all data compiled in this study.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   79 of 90 
15 REFERENCES  
1. Cocucci, E. and J. Meldolesi, Ectosomes and exosomes: shedding the confusion between 
extracellular vesicles.  Trends Cell Biol, 2015. 25(6): p. 364- 72. 
2. de Franchis, R. and V.I.F. Baveno, Expanding consensus in portal hypertension: Report of 
the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.  J Hepatol, 2015. 63(3): p. 743 -52. 
3. Durbin, A.P., et al., A 12 -Month- Interval Dosing Study in Adults Indicates That a Single Dose 
of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.  J Infect Dis, 2016.  
4. Lozano, R., et al., Global and regional mortality from 235 causes of death for 20 age groups 
in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.  
Lancet, 2012. 380(9859): p. 2095 -128. 
5. Global, regional, and national age– sex specific all -cause and cause -specific mortality for 
240 causes of death, 1990– 2013: a systema tic analysis for the Global Burden of Disease 
Study 2013.  The Lancet, 2015. 385(9963): p. 117 -171. 
6. Global, regional, and national incidence, prevalence, and years lived with disability for 301 
acute and chronic diseases and injuries in 188 countries, 1990– 2013: a systematic analysis 
for the Global Burden of Disease Study 2013.  The Lancet, 2015. 386 (9995): p. 743- 800. 
7. D'Amico, G., G. Garcia -Tsao, and L. Pagliaro, Natural history and prognostic indicators of 
survival in cirrhosis: a systematic review of 118 studies.  J Hepatol, 2006. 44 (1): p. 217 -31. 
8. Gines, P., et al., Compensated cirrhosis: natural history and prognostic factors.  Hepatology, 
1987. 7(1): p. 122 -8. 
9. D'Amico, G., et al., Competing risks and prognostic stages of cirrhosis: a 25- year inception 
cohort study of 494 patients.  Aliment Pharmacol Ther, 2014. 39(10): p. 1180- 93. 
10. Ripoll, C., et al., Hepatic venous pressure gradient predicts clinical decompensation in 
patients with compensated cirrhosis.  Gastroenterology, 2007. 133 (2): p. 4 81-8. 
11. Ripoll, C., et al., Influence of hepatic venous pressure gradient on the prediction of survival 
of patients with cirrhosis in the MELD Era.  Hepatology, 2005. 42 (4): p. 793 -801. 
12. Garcia -Tsao, G., et al., Prevention and management of gastroesophageal varices and 
variceal hemorrhage in cirrhosis.  Hepatology, 2007. 46 (3): p. 922 -38. 
13. D'Amico, G., et al., Hepatic vein pressure gradient reduction and prevention of variceal 
bleeding in cirrhosis: a systematic review.  Gastroenterology, 2006. 131 (5): p. 1611 -24. 
14. Garcia -Tsao, G., Current management of the complications of cirrhosis and portal 
hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis.  
Gastroenterology, 2001. 120(3): p. 726 -48. 
15. Ge, P.S. and B.A. Runyon, The changing role of beta- blocker therapy in patients with 
cirrhosis.  J Hepatol, 2014. 60 (3): p. 643 -53. 
16. Biecker, E., Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management.  World J Gastroenterol, 2013. 19 (31): p. 5035- 50. 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   80 of 90 
17. Conn, H.O., et al., Propranolol in the prevention of the first hemorrhage from 
esophagogastric varices: A multicenter, randomized clinical trial. The Boston- New Haven -
Barcelona Portal Hypertension Study Group.  Hepatology, 1991. 13(5): p. 902- 12. 
18. Serste, T., et al., Deleterious effects of beta- blockers on survival in patients with cirrhosis 
and refractory ascites.  Hepatology, 2010. 52(3): p. 1017 -22. 
19. Guicciardi, M.E. and G.J. Gores, Apoptosis as a mechanism for liver disease progression.  
Semin Liver Dis, 2010. 30 (4): p. 402 -10. 
20. Eguchi, A., et al., Emricasan, a pan caspase inhibitor, improves survival and portal 
hypertension in a murine model of long -term common bile- duct ligation.  Hepatology, 2015. 
62(S1): p. 952A.  
21. Lemoinne, S., et al., The emerging roles of microvesicles in liver diseases.  Nat Rev 
Gastroenterol Hepatol, 2014. 11 (6): p. 350 -61. 
22. Spada, A., P. Contreras, and G. Burgess. Inhibition of caspase activity with emricasan in 
HCV patients: Potential implications for chronic dos ing and long term safety . in AASLD . 
2012. Hepatol.  
23. Spada, A., et al. Physiologically normal levels of apoptosis in healthy volunteers are not 
reduced by the pan caspase inhibitor emricasan.  in AASLD . 2013. Hepatol.  
24. Shiffman, M.L., et al., Clinical trial: the efficacy and safety of oral PF -03491390, a 
pancaspase inhibitor -  a randomized placebo- controlled study in patients with chronic 
hepatitis C.  Aliment Pharmacol Ther, 2010. 31(9): p. 969- 78. 
25. Albillos, A. and G. Garcia- Tsao, Classification of cirrhosis: the clinical use of HVPG 
measurements.  Dis Markers, 2011. 31(3): p. 121- 8. 
26. Iwakiri, Y., Pathophysiology of portal hypertension.  Clin Liver Dis, 2014. 18 (2): p. 281 -91. 
27. Iwakiri, Y. and R.J. Groszmann, The hyperdynamic circulation of chronic liver diseases: from 
the patient to the molecule.  Hepatology, 2006. 43 (2 Suppl 1): p. S121- 31. 
28. Bolognesi, M., et al., Splanchnic vasodilation and hyperdynamic circulatory syndrome in 
cirrhosis.  World J Gastroenterol, 2014. 20(10): p. 2555- 63. 
29. Vorobioff, J.D. and R.J. Groszmann, Prevention of portal hypertension: from variceal 
development to clinical decompensation.  Hepatology, 2015. 61 (1): p. 375- 81. 
30. Qamar, A.A., et al., Lack of effect of non -selective beta -blockers on the hepatic vein 
pressure gradient (HVPG) in patients with mild portal hypertension: A tale of two studies.  
Hepatology, 2010. 52 (4). 
31. Villanueva, C., et al., Development of hyperdynamic circulation and response to beta -
blockers in compensated cirrhosis with portal hypertens ion. Hepatology, 2015.  
32. Bush, K., et al., The AUDIT alcohol consumption questions (AUDIT -C): an effective brief 
screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test.  Arch Intern Med, 1998. 158 (16): p. 
1789- 95. 
33. David, K., et al., Quality of life in adults with nonalcoholic fatty liver disease: baseline data 
from the nonalcoholic steatohepatitis clinical research network.  Hepatology, 2009. 49 (6): p. 
1904- 12. 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   81 of 90 
34. Younossi, Z.M., et al., Development of a disease specific questionnaire to measure health 
related quality of life in patients with chronic liver disease.  Gut, 1999. 45(2): p. 295- 300. 
35. Dan, A.A., et al., Health -related quality of life in patients with non- alcoholi c fatty liver 
disease.  Aliment Pharmacol Ther, 2007. 26 (6): p. 815- 20. 
36. Scaglione, S., et al., The Epidemiology of Cirrhosis in the United States: A Population- based 
Study.  J Clin Gastroenterol, 2015. 49(8): p. 690 -6. 
37. Muniyappa, R., et al., Current approaches for assessing insulin sensitivity and resistance in 
vivo: advantages, limitations, and appropriate usage.  Am J Physiol Endocrinol Metab, 2008. 
294(1): p. E15- 26. 
38. Guha, I.N., et al., Noninvasive markers of fibrosis in nonalcoholic fatty liver  disease: 
Validating the European Liver Fibrosis Panel and exploring simple markers.  Hepatology, 
2008. 47(2): p. 455 -60. 
39. Parkes, J., et al., Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in 
patients with chronic hepatitis C.  J Viral Hepat, 2011. 18 (1): p. 23 -31. 
40. Parkes, J., et al., Systematic review of the diagnostic performance of serum markers of liver 
fibrosis in alcoholic liver disease.  Comp Hepatol, 2012. 11(1): p. 5.  
41. Parkes, J., et al., Enhanced liver fibrosis t est can predict clinical outcomes in patients with 
chronic liver disease.  Gut, 2010. 59(9): p. 1245- 51. 
42. Machado, M.V. and H. Cortez -Pinto, Non-invasive diagnosis of non- alcoholic fatty liver 
disease. A critical appraisal.  J Hepatol, 2013. 58(5): p. 1007 -19. 
43. Sanyal, A.J., et al., Clinical and Histologic Correlates of the Hepatic Venous Pressure Gradient (HVPG) in Patients with Compensated Cirrhosis due to Nonalcoholic 
Steatohepatitis (NASH).  Hepatology, 2015. 62 (1 (Suppl)): p. 577A.  
44. Ghosh, S., et  al., Moderate exercise attenuates caspase- 3 activity, oxidative stress, and 
inhibits progression of diabetic renal disease in db/db mice.  Am J Physiol Renal Physiol, 
2009. 296(4): p. F700 -8. 
45. Trussell, J., Contraceptive failure in the United States.  Contraception, 2011. 83 (5): p. 397 -
404. 
46. CDC- U.S. Selected Practice Recommendations for Contraceptive Use, 2016.  Morbidity and 
Mortality Weekly Report, 2016. 65(4): p. 1 -66. 
47. Pais, R., et al., A systematic review of follow -up biopsies reveals disease progression in 
patients with non- alcoholic fatty liver.  J Hepatol, 2013. 59 (3): p. 550 -6. 
48. Davidoff, F., et al., Sponsorship, authorship, and accountability.  N Engl J Med, 2001. 
345(11): p. 825 -6; discussion 826- 7. 
49. Alberti, K.G., et al., Harmonizing the metabolic syndrome: a joint interim statement of the 
International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; 
International Atheroscleros is Society; and International Association for the Study of Obesity.  
Circulation, 2009. 120 (16): p. 1640- 5. 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in 
Subjects with Non -Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   82 of 90 
Appendix I. Schedule of Events  
 
Screening  
Wk -6 to Day 0  Double -blind Treatment Phase  
Follow -up Initial  24 weeks  Continued 24 weeks  
Day 1  Wk 4  Wk 8  Wk 12  Wk 16  Wk 20  Wk 24  Wk 32  Wk 40  Wk 48  2 wks after 
Wk 24 or 48   
±5 
Days  ±7 
Days  ±7 
Days  ±7 
Days  ±7 
Days  ±7 
Days  ±10 
Days  ±10 
Days  ±10 
Days  ±7  
Days  
Study Procedures              
Informed consent  X       X     
Eligibility criteria  X X           
Medical and surgical history  X            
Concomitant medication review  X X X X X X X X X X X X 
Vital signs, weight, Child -Pugh  X X X X X X X X X X X X 
Physical examinationA  X X X X X X X X X X X X 
12 Lead ECG  X  X     X   X X 
AUDIT, Skinner questionnaires  X            
AUDIT -C questionnaire      X   X   X  
Liver/gallbladder ultrasoundB X            
EsophagogastroduodenoscopyC X            
SF-36 and CLDQ   X      X   X  
HVPG (with blood samples)  X       X     
Adverse event assessmentD X X X X X X X X X X X X 
Study drug dispensation   X X X X X X XE X X   
Compliance assessment    X X X X X X X X X  
Methacetin breath testF X       X   X  
Transient elastographyF  X       X   X  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in 
Subjects with Non -Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   83 of 90 
 
Screening  
Wk -6 to Day 0  Double -blind Treatment Phase  
Follow -up Initial  24 weeks  Continued 24 weeks  
Day 1  Wk 4  Wk 8  Wk 12  Wk 16  Wk 20  Wk 24  Wk 32  Wk 40  Wk 48  2 wks after 
Wk 24 or 48   
±5 
Days  ±7 
Days  ±7 
Days  ±7 
Days  ±7 
Days  ±7 
Days  ±10 
Days  ±10 
Days  ±10 
Days  ±7  
Days  
Laboratory Evaluations              
Chemistry  XG X X X X X X X X X X X 
Hematology  X X X X X X X X X X X X 
Coagulation  X X X X X X X X X X X X 
Urinalysis  XH XH X X X X X X X X X X 
α-fetoprotein, etiologic screen  X            
MetabolicI   X      X   X  
Fibrosis markers   X      X   X  
Transporter genotyping   X           
Population PK    X X X X X X X X X  
Biomarkers (peripheral blood)  X X X X X X X X X X X X 
Serum pregnancy testJ X X           
Urine pregnancy  testJ  X X X X X X X X X X X 
A Comprehensive physical exam ination at Screening, Week 24, Week 48. Focused physical exam ination at all other visits.  Height at Screening only.  
B If subject had a liver and gallbladder ultrasound within three months of Screening and a report with the required information is available, the prior ultraso und 
can be used for the study.  
C If subject had a prior  esophagogastroduodenoscopy  (EGD) according to Baveno VI recommendations and a report with the required information is available, 
the prior EGD can be used for the study . 
D Includes assessment for biliary colic symptoms and qualifying clinical outcome events . 
E For subjects who sign consent for the second 24-week treatment phase only . 
F At select sites . 
G AST, ALT, and total and direct bilirubin measured twice during screening at least 2 weeks apart .  
H Including quantitative protein and creatinine  
I After fasting at least 10 hours .  
J For females of reproductive potential . 
 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   84 of 90 
Appendix II. Measurement of Liver Metabolic Function with the Methacetin Breath Test  
The 13C-methacetin breath test (MBT) is a noninvasive tool to assess liver microsomal capacity 
to metaboliz e the nonradioactive 13C-labeled Methacetin. The Breath Test System consists of 
the BreathID® MCS device and a test kit containing a breath collection nasal cannula and a 
nonradioactive isotope 13C-methacetin solution. The BreathID MCS device measures and 
computes the 13CO 2/12CO 2 ratio in the subject’s exhaled breath in real time.  
Subject will be asked to sit in a chair and the nasal cannula (a small tube) will be placed beside 
their nostrils. Attached to the nasal cannula will be the BreathID MCS device. The BreathID 
MCS device will be activated for approximately 10 minutes and it will collect the subject’s carbon 
dioxide while breathing normally. This process can take up to a maximum of 25 minutes if the 
device needs to self -calibrate . 
One cup of a solution of a 75mg Methacetin pre -dissolved in water will be administered to the 
subject.  Methacetin is exclusively broken up in the liver and turns into carbon dioxide and acetaminophen (Tylenol
®). The amount of carbon dioxide is measured by the BreathID MCS 
device, and will indicate the liver’s metabolic capacity to metabolize 13C-Methacetin.  
Subjects will be asked to remain sitting in a chair with the nasal cannula in their nose breathing 
in a normal fashion for the next 60 minutes. Then the nasal cannula will be removed and 
subjects may leave the testing room.  
The full breath test procedure could take up to 1.5 hours.  
The actual MBT  measure that will be used is the cPDR 30, which is the cumulative percentage 
dose recovery of the metabolized 13C-methacetin 30 minutes after ingestion of the test 
substrate. It is obtained using the following steps:  
1. All delta over baseline (DOB) measures with corresponding time -point (T n) will be noted on 
the CRF. Each DOB will be plotted by the BreathID MCS device using the following formula:  
DOB = 13CO 2/12CO 2 @T n - 13CO 2/12CO 2 @T 0 
 Where T
0 is the baseline sample time (0) and T n is the time of the post ingestion sample in 
minutes.  
 
2. The DOBs will be transformed into percentage dose recovery rates (PDR) at a specific time 
point (n) by using the following formula:  
PDR n=0.01817853 × DOB n × w0.5378  × h0.3963 
 
While: w = weight (in kg), h = height (in cm)  
 
3. The following formula will be used to obtain cPDR 30: 
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐30= 𝑇𝑇1
60∙𝑐𝑐𝑐𝑐𝑐𝑐1
2+�𝑇𝑇𝑛𝑛−𝑇𝑇𝑛𝑛−1
60∙(𝑐𝑐𝑐𝑐𝑐𝑐𝑛𝑛− 𝑐𝑐𝑐𝑐𝑐𝑐𝑛𝑛−1)
2𝑛𝑛
𝑖𝑖=2+𝑇𝑇𝑛𝑛−𝑇𝑇𝑛𝑛−1
60∙𝑐𝑐𝑐𝑐𝑐𝑐𝑛𝑛−1 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   85 of 90 
The company developing the breath test, Exalenz Bioscience, will obtain access to the subject’s 
study data including all the breath test parameters as well as the subject’s demographic, 
imaging, and laboratory data. Exalenz Bioscience will be using these  data in order to develop 
and validate diagnostic  and/or  prognostic , and/or monitoring algorithms for this study population. 
Exalenz Bioscience may segregate a portion of the subject data for use of approval of the 
breath test and its algorithm(s).  
The following precautions should be observed prior to the MBT : 
• Subject should be fasting, including all oral morning medications (except for beta 
blockers  and study drug [emricasan or placebo] ), for at least 8 hours prior to the MBT   
• Subject should not smoke on the day of the breath test prior to the MBT  
• Subject should not take any of the following drugs within 48 hours prior to the MBT : 
acyclovir, allopurinol, carbamazepine, cimetidine, ciprofloxacin, daidzein (herbal), disulfiram, echinacea, enoxacin, famotidine, fluvoxamine, methoxsalen, mexiletine, 
montelukast, norfloxacin, phenylpropanolamine, phenytoin, propafenone, rifampin, 
terbinafine, ticlopidine, thiabendazole, verapamil, zileuton or any medication that might 
interfe re with methacetin metabolism or might affect CYP 1A2 (cytochrome P450 1A2)   
• Subject should not take amiodarone within 30 days prior to the MBT  
• Subject should not take paracetamol (acetaminophen) related medications within the 
24 hours prior to the MBT  
• Subjects should not perform the MBT if allergic or hypersensitive to methacetin or its 
metabolites (paracetamol, acetaminophen)  
• Subject should not consume any alcohol or caffeine within 24 hours prior to the MBT  
• Subject should not have general anesthesia or sedation within 24 hours prior to the MBT  
• Subjects on beta -blockers or statins should be on stable dose at least 30 days prior to 
the MBT  
 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   86 of 90 
Appendix III. FibroScan® Protocol  
Background  
Transient  elast ography performed  with FibroS can® uses  a low frequenc y vibrator (50H z) 
mounted on 1-D US probe  (5MHz). The speed  of propagation of the shear  wave  through the 
liver is proportional  to stiffness.  The stiffness  correlates with the severi ty of fibrosis. 
Figure 5. FibroScan® Probe Placement in Relation to Anatomy of a Subject  
 
Source:  Reproduced from Ziol et al 2005  
 
There  are three images displayed on the monitor: 
1. A-mode image 
2. Time movement image  
3. 2D elastogram  
 
These images are used  by the operator to make sure that the area of the liver selected is free of 
large vascular structures, that lung fields do not encroach on inspiration and that the selected 
area is not over a rib. The elastogram demonstrates the depth  of the shea r wave with time.  The 
slope of  the resulting  line gives speed of propagation. 
Method 
1. The subject is asked to lie comfortably in the supine position with his/her right arm fully 
abducted and resting on a pillow.  
2. Cover the tip of the probe with a small amount of coupling gel and place on the skin, on the 
right lateral wall of the abdomen between the ribs at the level of the right lobe of the liver.  
3. The right lobe of the liver is selected to ensure that the area of the liver to be measured is at 
least 6 c m thick.  
4. The probe must be placed perpendicular to the subject’s abdominal wall.  

 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   87 of 90 
5. Pressure should be applied by the operator  on the subject  and the button is pressed  to 
initiate an acquisition.  
a. It is important to apply enough pressure on the subject so that  the pressure bar display 
is within the green range. Insufficient pressure will be displayed as orange and over 
pressure will be displayed as red.  
b. Pressure must be released immediately following an acquisition.  
c. When making a measurement, it is also important to ensure that the subject is breathing 
slowly and not moving or speaking.  
6. If a successful  reading is not  acquired,  the probe should be moved up or down by one rib 
space and, if that is not successful,  anteriorly or posterior ly from the initial site by 1cm. Once  
a successf ul readi ng has been obtained,  the remaining  readings shoul d be taken from th e 
same site. 
7. For each subject, the following  paramet ers should be recorded:  
a. The median liver stiffness value kPa 
b. The inter -quartile (IQR) range kPa  
c. Success rate (%)  
8. To obtain a reliable and represent ative evaluation of the stiffness  of the liver, the following 
criteria should be met:  
a. 10 valid measurements should be acquired  
b. Success rate >60%  
c. IQR/median <30%  
If any of these criteria are not met, the test should be repeated.  
Additional Recommendations  
The following recommendations are being provided in order to improve standardization of the 
FibroScan® procedure. Please implement these recommendations to obtain consistent and 
reproducible measurements.  
1. The subject should be NPO for 4 hours prior to the procedure  
2. The operator should be seated next to the subject, with the hand holding the probe, 
stabilized by the other. This will improve the stability of the probe as it is held up against the 
patient yielding an improved result with a low IQR.  
3. The measurement should be taken during expiration.  
4. Investigators should use the appropriate probe (normal or XL) for a subject according to 
their level of adiposity and use the same probe consistently for all measurements for that 
subject during the course of the study.  
 
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   88 of 90 
Appendix IV. Diabetes Mellitus Definition and Met abolic Syndrome C riteria  
The diagnosis of diabetes mellitus  is based on criteria established by the American Diabetes 
Association:  
• HbA1c ≥6.5% (using a certified method standardized to the Diabetes Control and 
Complications Trial assay) OR  
• Fasting plasma glucose ≥ 126 mg/dL  (7 mmol/L) (confirmed by repeat testing unless 
there is unequivocal hyperglycemia) OR  
• 2-hr plasma glucose (≥200 mg/dL [11.1 mmol/L) after 75 -gram oral glucose tolerance 
test OR  
• Random plasma glucose ≥200 mg/dL (11.1 mmol/L) with symptoms of hyperglycemia or 
hyperglycemic crisis  
 
The metabolic syndrome is a cluster of risk factor for cardiovascular disease and type 2 diabetes mellitus including elevated blood pressure, dyslipidemia (elevated triglycerides and low 
HDL cholesterol), elevated fasting glucose, and central obesity.  Various diagnostic c riteria have 
been proposed by different scientific organizations in the past, with the main difference concerning the measure for central obesity.  In 2009, the International Diabetes Federation Task 
Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American 
Heart Association; World Heart Federation; International Atherosclerosis Society; and 
International Association for the Study of Obesity issued a joint statement proposing a 
harmonized definition of the metabolic syndrome [49].  The criteria for diagnosis are 
summarized in Table 1 and Table 2.  
 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   89 of 90 
 
Source: Alberti et al. Circulation, 2009. 120 (16): p. 1640-5.  

 Document Code:  IDN-6556- 14-PRO -1001  
Version:  9.0 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Trial of Emricasan, 
an Oral Caspase Inhibitor, in Subjects with Non- Alcoholic Steatohepatitis (NASH) 
Cirrhosis and Severe Portal Hypertension  
 
CONFIDENTIAL   90 of 90 
 
Sour ce: Alberti et al. Circulation, 2009. 120 (16): p. 1640-5.  
 

Signature Page for CTS-CTD-3625 v1.0 
Signature Page for CTS-CTD-3625 v1.0 Approved Heidi Spanish
Document Owner
20-Mar-2018 22:22:16 GMT+0000
Approved Jean Chan
Monitoring
20-Mar-2018 22:26:35 GMT+0000
Approved David Hagerty
Clinical Operations
20-Mar-2018 23:35:44 GMT+0000
Approved Dan Ripley
Project Management
21-Mar-2018 01:30:19 GMT+0000
Approved Edward Smith
Regulatory
21-Mar-2018 17:06:27 GMT+0000
Approved Cathryn Bennett
Clinical Operations
21-Mar-2018 18:53:33 GMT+0000